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RÉSUMÉ 
 
La vaccination est largement utilisée pour la génération de lymphocytes T spécifiques contre les 
tumeurs. Malheureusement, cette stratégie n'est pas adaptée aux personnes âgées car leur thymus 
régresse avec l'âge conduisant ainsi à une baisse dans la production de cellules T et à 
l'accumulation de cellules immunitaires âgées ayant des défauts liés à leurs stimulations. Comme 
il a été démontré auparavant que L’IL-21 est capable d’induire des fonctions thymiques, nous 
avons émis l’hypothèse que l’injection d’IL-21 à des souris âgées stimulera la thymopoïèse. Nos 
résultats montrent que l’administration de l’IL-21 augmente le nombre absolu de thymocytes 
chez les souris âgées et augmente la migration de ces cellules vers la périphérie ou ils contribuent 
à la diversité du TCR. De plus les cellules T en périphérie expriment un niveau plus élevé de 
miR181-a, et par conséquent moins de phosphatase comme SHP2, DUSP5/6 qui inhibent le 
TCR. En vaccinant des souris âgées avec le peptide Trp2, les souris traitées avec l’IL-21 
montrent un retard dans la croissance des cellules B16 tumorales. Cette étude montre que l’IL-21 
pourrait être utilisé comme stratégie pour le rétablissement du systeme immunitaire chez les 
personnes âgées. 
 
 
 
 
 
 
 
Mots clés: Involution thymique; Interleukine-21; Cellules T; Signalisation; miR-181a; Vaccin. 
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ABSTRACT 
 
Vaccines have been largely sought for the generation of protective tumor-specific T cells. 
Unfortunately however, this strategy is not suitable for the elderly as their thymus regresses with 
age leading to a decline in T-cell production and accumulation of aged lymphocytes endowed 
with stimulation-related defects. Interleukin (IL)-21 has been shown to display thymo-
stimulatory properties. Therefore, we hypothesized that IL-21 administration to ageing host may 
boost T-cell production and restore a competent peripheral T-cell compartment. Our study shows 
that IL-21 injection to aged mice lead to an increase in the thymocytes absolute number and an 
increase in thymocytes egress to the periphery where they enhance the T-cell receptor (TCR) 
diversity. Furthermore T-cell in the periphery express higher level of miR-181a and thus less 
TCR-inhibiting phosphatases SHP-2 and DUSP5/6 enable them to be more responsive upon 
stimulation. Consequently, aged rIL-21-treated mice vaccinated using a tyrosinase-related 
protein 2 (Trp2)-derived peptide exhibited a substantial delay in B16 tumor growth and 
improved survival. The results of this study highlight the immunorestorative function of rIL-21 
paving its use as a strategy for the re-establishment of effective immunity in the elderly. 
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PREFACE 
lmost 50% of cancer cases are diagnosed in patients aged 60 years and older. As 
more than 25% of the total U.S. population will reach the age of 60 by 2050, the 
number of patients suffering from cancer is expected to rise. Since living standards 
and overall healthcare are improving worldwide, a higher life expectancy requires the adoption 
of novel strategies aimed at keeping the aging population healthy. Although most cancer types 
can be removed by surgery, followed by radiation and/or chemotherapy, these multimodality 
therapies are ineffective against spread metastases. Cancer vaccination represents therefore an 
appealing alternative due to its limited toxicity and ability to stimulate the host's own immune 
system to seek and destroy metastatic cancer cells. Unfortunately however, vaccines are less 
effective at older age due to impaired T-cell responsiveness due to immunosenescence; a 
degeneration of the immune system caused by thymic atrophy. As a result, the output of newly 
developed naïve T cells endowed with the capacity of effectively responding to new antigenic 
challenges dramatically decreases pocking major holes in patients’ immunocompetency. Thus, 
there is an urgent need for the development or improvement of immunotherapies to suit the 
elderly population. The study described herein will highlight the utility and potency of 
interleukin (IL)-21 at stimulating de novo thymopoiesis to rejuvenate the immune system of 
aged subjects. Optimising and adopting such concept will lead to innovative IL-21-based 
strategies directed against two key elderly-related health problems: i) providing superior 
responsiveness to cancer vaccines, and ii) reducing the emergence and/or cancer relapse in this 
vulnerable population. Therefore, the favourable outcome of this study will have significant 
ramifications on the future use of IL-21 in the context of preventive/therapeutic cancer 
vaccination measures aimed at enhancing anti-tumoral immunity of the aging population. 
A 
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1.0 - Aging and Thymopoiesis 
One of the most important attribute of adaptive immunity is its capacity to discriminate between 
self and non-self-antigens (1). In order to achieve that, its main components, B and T 
lymphocytes, must undergo restricted processes during their development (2). In jawed 
vertebrates including humans, B and T cells develop at distinct anatomical sites, the former in 
the bone marrow (BM) or fetal liver and the latter in the thymus (2). From an evolutionary point 
of view, we can assume that the thymus emerged as a dedicated environment to facilitate and 
support the development of self-tolerant T cells expressing a diverse repertoire of T-cell receptor 
(TCR) (3). Failure to build or maintain a proper thymus can lead to defects ranging from 
immunodeficiency to autoimmunity (4). 
 
The main thymus-associated limitation is the progressive decrease of its function with age; a 
phenomenon known as thymic involution (5). Age-associated thymic involution occurs in all 
species, indicating that this process is evolutionary ancient and conserved. It is characterized by a 
reduction in mass, cellularity as well as loss of normal architecture consequently leading to a 
decrease in T-cell development (thymopoiesis) (6). As a result, diminished production of naïve T 
cells and attrition of TCR repertoire in aging hosts is amenable to increased susceptibility to 
infectious diseases, cancers and autoimmunity (6). From a general perspective, thymic involution 
can be considered as a natural leading global health problem. Thus, a tremendous amount of 
effort is put to prevent or reverse age-associated thymic involution as a mean to ensure the well-
being of the aging society.  
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1.1 - Thymus structure 
The thymus (FIGURE 1) consists of two distinct lobes connected by connective tissues and 
surrounded by capsular tissues (7). Histologically, each lobe can be subdivided into four major 
compartments each having a distinct role in thymopoiesis. The four compartments include the 
subcapsular zone, the cortex, the medulla, and the cortico-medullary junction (4). The 
subcapsular zone contains mainly cortical thymic epithelial cells (cTECs), whereas the cortex 
contains a mix of cTECs, fibroblasts and macrophages. The medulla is comprised of medullary 
thymic epithelial cells (mTECs) and dendritic cells (DC). The cortico-medullary junction is the 
vascular region where thymic arteries enter the organ. The stroma is considered as the non-
hematopoietic component of the thymus and contains keratin positive and negative cells. Keratin 
positive cells represent TECs and it is divided into keratin5- keratin8+ (K5-k8+ for cTECs) and 
keratin5+ keratin8- (k5+k8- for mTECs) cells. Keratin negative cells are a mixture of fibroblasts, 
non-fibroblastics mesenchymal cells and endothelial cells (4). The thymus stroma is essential to 
the regulation of T-cell development and selection. For example, TECs secrete chemokine and 
growth factors and express cell surface molecules all involved in supporting migration and 
development of progenitor cells (8). In addition, TECs present distinct peptide repertoires 
essential for central tolerance (8). During thymic involution, the thymus stroma degenerates and 
is subsequently replaced by adipose tissue, which negatively interferes with thymopoiesis. 
 
1.2 - Intrathymic T-cell development 
Thymopoiesis involves several differentiation and proliferation events during which cross-talks 
between stromal and lymphoid cells take place (10) (FIGURE 1). Lymphoid progenitor cells  
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FIGURE 1: THYMIC STRUCTURE AND T-CELL DEVELOPMENT.  
A simplified overview of the thymus defined regions and stages of T-cell development. 
(Blackburn CC et al. Nature Reviews Immunology 4, 278-289 (2004) (9). 
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migrate from the BM, enter the thymus via the cortico-medullary junction, and undergo four 
stages of maturation as they pass from the subcapsular zone through the cortex and to the 
medulla before reaching finally peripheral circulation as immature naïve T cells (7). For that to 
happen, T-cell migration to and through the thymus is guided by chemokines produced by 
thymic stromal cells in distinct regions or microenvironments, and developing thymocytes seem 
to find their way by sequentially expressing different chemokine receptors specific for the 
transition between each stage of maturation (11). Developing thymocytes are sub-divided into 
three major groups based on the expression of CD4 and CD8 on their cell surface. They start as 
double-negative (DN) cells that do not express CD4 or CD8 and after different maturation 
processes they become double positive (DP) cells expressing both CD4 and CD8. They finally 
become single-positive (SP) T cells expressing either the CD4 or CD8 co-receptor (11). DN 
thymocytes can be further sub-divided into four sub-populations according to their expression of 
CD44 and CD25: DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-CD25+), and DN4 
(CD44-CD25-). The first step in T-cell development is the migration of lymphoid progenitor cells 
or thymic seeding progenitors (TSP) from the BM to the thymus. This step is controlled by the 
adhesive interaction between platelet P-selectin glycoprotein ligand 1, which is expressed by 
circulating TSP, and P-selectin found on the surface of thymic endothelium. They enter the 
thymus via the vasculature at the cortico-medullary region and become early thymic progenitors 
(ETPs) (the most important sub-population of the DN1 fraction). ETPs still retain the potential 
to give rise to DC, natural killer (NK), and macrophages, but they lose their multipotency as they 
differentiate and become restricted to the T-cell lineage (12). The first checkpoint in the 
developmental process of T cells is the T lineage commitment at the DN1/DN2 stages. In order 
to become committed to the T-cell lineage, DN1 cells interact with the delta-like 4 (DL4) ligand 
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expressed on cTECs through their Notch1 receptor (11). In addition, cTECs secrete interleukin 
(IL)-7 which supports their differentiation process. DN2 differentiate to DN3 in the subcapsular 
zone and during this transition the αβ versus γδ T cells fate is specified. The DN3 cells follow 
another checkpoint known as the β-selection where only DN3 who have successfully rearranged 
the β-chain of the TCR survive by receiving a signal through a functional pre-TCR complex (11). 
Thymocytes that have been selected proceed to the DN4 stage, initiate CD4 and CD8 expression 
and become DP thymocytes in the cortex. At that point, DP cells initiate the TCRα gene 
rearrangement resulting in the expression of TCRαβ complexes. DP cells in the cortex will then 
undergo positive selection where only thymocytes with a functional TCR capable of recognizing 
self-peptide-MHC complexes presented by cTECs receive a survival signal and differentiate into 
SP cells (13). Surviving DPs will then express the C-C chemokine receptor type (CCR) 7, which 
guides them to the medulla in response to CCR7 ligands (C-C motif ligand (CCL)19 and 
CCL21). In the medulla, mTECs and DCs will express and present tissue-specific antigens to SP 
cells to negatively select any TCR with self-reactive potential in order to avoid generating 
reactive T cells capable of causing autoimmunity (13). SP thymocytes will spend ~12 days in the 
medulla whereby they will express the sphingosine-1-phosphate receptor 1. At that time point, 
CD4 or CD8 T cells egress from the thymus and continue their maturation in the periphery for an 
additional period of three weeks (13). 
 
1.3 - Thymic Involution from an Evolutionary Perspective 
Thymic involution is characterized by the expansion of perivascular space due to adipocytes 
accumulation with age shifting the ratio of thymic epithelial space (TES) to perivascular space 
(5). Consequently, the TES represents less than 10% of total thymic tissue by the age of 70 (5). 
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Such thymic regression results in constriction of peripheral T-cell diversity, alterations in their 
phenotype and function, and corrosion of telomeres causing replicative senescence (6). Age-
associated thymic involution has been suggested to occur in all species, indicating that this 
process is evolutionary ancient and conserved (14). If so, are there any benefits to thymic 
involution? The human life span has extended drastically over the last centuries due to decline in 
infectious disease-caused mortality owing to improved sanitation, medical care as well as 
development of vaccines and antibiotics (15). This means that the immune system, which was 
once "designed to serve for almost 40 years" has to provide continuous protection for the decades 
to come (16). Of all evolutionary hypotheses, the "disposable soma theory", which suggests that 
the body must budget its available amount of energy between locomotion, thermogenesis, 
growth, reproduction and repair appears to be highly compatible with thymic involution as the 
thymus is an "energy expensive organ" due to the fact that more than 90% of all developed 
thymocytes die daily (17). Under such context, thymic involution is divided in two main stages 
and may be regulated by different mechanisms (18). The first stage occurs early in life mostly at 
6 weeks of age in mice and at one year after birth in humans (19). This early thymic involution is 
believed to happen as newborns have essentially an ''empty'' peripheral immune compartment 
(20). Thus, the thymus increases its T-cell output capacity for the purpose of populating the 
peripheral immune-based compartment (18). Once this task fulfilled, thymic size and output are 
reduced (18). The second thymic involution wave is gradual throughout life and starts after 
puberty (24). Briefly, the TES begins to involute at a rate of 3% per year until middle age (35-45 
years) and continues afterwards to decrease at a rate of 1% per year throughout the rest of life 
(5). Little is known about the precise mechanisms that lead to the second stage of thymic 
involution, but a substantial amount of evidence suggests that both extrinsic and intrinsic factors 
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may be involved (5). In fact, acute thymic involution caused by extrinsic stimuli continuously 
occur especially when energy and resources are scarce in certain conditions including starvation, 
malnutrition and pregnancy (18). In support of this notion, the exogenous administration of the 
energy intake regulating hormone leptin has been shown to prevent thymic atrophy (21). 
  
1.4 - Factors Causing Thymic Involution 
It is well established nowadays that thymic involution is based on two essential factors: i) a 
defect in the survival/proliferation/differentiation abilities of the pre-thymic hematopoietic 
progenitor pool, and ii) the precious loss of TECs (22). In support of the former point, several 
studies have shown that transplanting BM derived from aged mice into irradiated recipient 
younger hosts is less efficient at reconstituting the hematopoietic system (23). This is explained 
by the fact that aging hematopoietic stem cells (HSCs) are biased towards myeloid 
differentiation (24). Interestingly however, when young BM is transferred to aged recipient mice, 
a decrease in thymic reconstitution was also observed indicating that alterations in thymic 
microenvironment can also negatively impact thymopoiesis (25). Such alterations can be caused 
by stress factors capable of disrupting the homeostatic balance of the immune system (FIGURE 
2). For example, physiological stress such as malnutrition, infections, irradiation, and pregnancy 
trigger transient but reversible acute thymic involution (6). This is different from chronic age-
associated thymic involution in that acute atrophy is characterized by enhanced death of 
thymocytes followed by a recovery phase after the insult has been removed (18). So far, no 
approved treatments are available to protect against acute and/or chronic thymic atrophy, thereby 
leaving the immune system compromised under these conditions.  
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FIGURE 2: EXTRINSIC FACTORS AFFECTING THYMUS HOMEOSTASIS.  
Besides age-related chronic involution, several extrinsic factors can cause acute thymic atrophy 
including viral or bacterial infections, strong inflammation, malnutrition or pre-conditioning 
treatments such as chemo- or radiotherapies given prior to some medical interventions.  
GH, Growth Hormone. (Patel K. et al. Biology Reports 2009) (25). 
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1.5 - Experimental Strategies to Reconstitute the Thymus 
There is a growing body of evidence that the thymic tissue is plastic and that the involution 
process might be therapeutically halted or reversed. Therefore, understanding the processes 
triggering declines in thymic function during aging would help in the development of strategies 
that can reverse thymic atrophy and improve the overall outcome of immunocompromised 
patients. As restoration of immune competence is critically dependent on residual thymic 
function, most attempts to regenerate the thymus involve factors targeting the stromal 
compartment. Of all strategies developed so far, we will only provide a brief overview on the 
most promising ones. 
 
1.5.1 - Sex Steroid Ablation (SSA) 
The decline in size and function of the thymus is more pronounced from the onset of puberty, 
which fits the increase in circulating sex steroids at that time (27). Therefore, increased sex 
steroids secretion during puberty has been proposed to contribute to the process of thymic 
involution. Several studies have validated this hypothesis either by administering sex steroids 
(androgens or estrogens) in young pre-pubertal mice to promote thymic involution or through 
their neutralization as a mean to inhibit/reverse thymic involution (27). Mechanistically, steroid 
hormones mediate their biological effects by interacting with their cognate receptors. Androgen 
and estrogen receptors are expressed in male and female thymi in both the hematopoietic and 
stromal compartments (28). In most instances, after binding its respective sex steroid, the 
receptor translocate to the nucleus where it directly mediates changes in the expression of target 
genes. As a result, male sex steroids induce CD4+CD8+ DP thymocytes apoptosis though the up-
regulation of tumor-necrosis factor-α, (29) while estrogens trigger thymic atrophy by eliminating 
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ETPs and inhibiting the proliferation of thymocytes at the β-selection stage (30). Based on these 
observations, SSA was proposed as a rational strategy to boost thymic function and promote 
thymic rejuvenation in young and adult subjects (FIGURE 3). Although surgical castration 
displays beneficial effects on thymic cellularity, architecture, organization, and enhances 
thymopoiesis in both young and adult animals, its therapeutic translation cannot be ensured due 
to its irreversible effects and ethical considerations (except for prostate cancer patients). 
However, a transient and reversible approach using compounds targeting the upstream signaling 
events such as the luteinizing hormone releasing hormone (LHRH) or directly blocking sex 
steroid receptors originally developed for prostate and breast cancer patients can be used (31). 
For instance, mice treated with the LHRH-agonist Lupron (aka ASC-J9) showed an increase in 
the number of lymphoid and myeloid progenitors in the BM and increased thymic and splenic 
recovery after BM transplantation (BMT) (32). In addition, clinical trials of SSA have shown 
that the use of LHRH-agonist in a small cohort of prostate cancer patients between 60 and 77 
years enhances thymic function (increased levels of naïve CD4+ and CD8+ T cells and NK counts 
4 months post-treatment) (24). Analysis of thymic function by measuring recent thymic 
emigrants by TCR excision circles (TREC) revealed that 8 of the 10 patients showed an increase 
in the total TREC+ cells/ml of blood compared to placebo (24). Similarly, a non-randomized 
pilot study involving patients undergoing BMT showed a significant increase in naïve TREC+ T 
cells with the use of the LHRH-Agonist Goserelin (33). These clinical studies clearly 
demonstrate that SSA represents a valid strategy to enhance thymic function, not just in 
immunocompromised patients, but also during aging. However, the systemic effects of SSA in 
the long term run is not yet clear nor are the potential systemic side effects. Thus, more in depth 
investigations are required to assess the safety of SSA-based compounds. 
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FIGURE 3: OVERVIEW OF THE HYPOTHALAMIC–PITUITARY–GONADAL AXIS 
AND ITS IMPLICATION IN REGULATING THYMIC FUNCTION.  
SSA using LHRH-R inhibitors or anti-androgen receptors (AR), blocks the negative effects of 
sex steroids on BM and the thymus and promotes their rejuvenation in steady-state conditions as 
well as following immune insults. LHRH, Luteinizing Hormone Releasing Hormone; LH, 
Luteinizing Hormone; FSH, Follicle Stimulating Hormone; GVHD, Graft Versus Host Disease; 
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CTP, Circulating Bone Marrow-Derived T-lineage Progenitor. (Velardi E. et al. Bone Marrow 
Transplant 2015. 50, S77–S81) (32). 
 
1.5.2 - Keratinocyte Growth Factor (KGF): the Stalwart of Thymic Epithelium Protection 
In the thymus, KGF is produced by thymic stromal cells and thymocytes, but its receptor 
(KGFR) is only expressed by TECs (35). KGFR-deficient mice have arrested thymic 
development (35). In contrast, an increase in the proportion of naïve T cells is observed 
following KGF administration to mice undergoing allogeneic BMT (36). Because KGFR is 
expressed by many organs targeted by alloreactive T cells, several research groups studied the 
effects of KGF in the setting of acute graft-versus-host disease (GVHD). Administration of KGF 
under such context led to: i) facilitated allo-engraftment, ii) alleviated GVHD, iii) protected and 
repaired epithelial cell in the gut mucosa, iv) reduced inflammatory cytokine release, and v) 
diminished allogeneic T-cell responses (36). Furthermore, KGF was recently reported to inhibit 
Ink4a expression; a tumor-suppressor gene repressing proliferation of T-cell progenitors (37). 
This was unexpected as KGFR is exclusively expressed by TECs. To explain this contradictory 
finding, Berent-Maoz et al. suggested that KGF triggers TECs to secrete soluble factors, which 
act on T-cell progenitors and down-regulate Ink4a expression (37). As a result, the proliferative 
potential of ETP and DNs is increased leading to enhanced T-cell progenitors output. KGF may 
therefore protect TECs while stimulating thymopoiesis to levels sufficient to boost the peripheral 
pool of naïve T cells and improve impaired immune functions. To validate these observations 
clinically, two separate phase I/II trials were conducted on patients undergoing allogeneic BMT 
(38). Although treated patients displayed ameliorated mucositis, an inflammation and ulceration 
of the mucous membranes lining the digestive tract, no significant improvements were observed 
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with respect to the incidence and severity of acute GVHD, T-lymphopoiesis, infections, overall 
survival, or cancer relapse rates (39). Altogether, KGF ameliorates mucotoxicity following 
allogeneic BMT without any favourable impact on immune recovery in patients. 
 
1.5.3 - Ghrelin (GRL) 
GRL is a 28 amino acid mature polypeptide released from the stomach into the circulation where 
it stimulates the feeding center of the hypothalamus to induce hunger (41). The GRL receptor 
(GRLR), on the other hand, is highly expressed by the pituitary gland, the central nervous 
system and on various immune cells (40). GRL administration has been shown to inhibit 
adipogenesis and inflammation in various preclinical models whereas its deficiency leads to 
reduced thymopoiesis and increased thymic adiposity (40). As thymic involution is naturally 
accompanied by adipocytes accumulation and increased production of pro-inflammatory 
cytokines, a role for GRL in reversing age-related thymic involution was proposed (40). To this 
end, Dixit et al. demonstrated that GRL administration to 14-22 months aged mice resulted in: i) 
increased thymic size and cellularity, ii) loss of thymic adipocytes, iii) increased number of both 
c- and mTECs, ETPs, recent thymic emigrants (RTEs), and finally iv) improved TCR diversity 
(40). Although GRL shows impressive pleiotropic thymopoietic-stimulating effects, its use as a 
potential therapy may be limited by the progressive loss of thymic GRLR expression with aging 
(40).  
 
1.5.4 - IL-7: The First Thymopoietin 
Initially discovered in 1988 as a murine B-cell precursor growth factor, IL-7 was quickly found 
to enhance: i) expansion of naïve peripheral CD4 and CD8 SP T cells, ii) antiviral/antitumour 
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activity of cytotoxic T cells, and iii) survival/proliferation of CD8 memory T cells (42). Based on 
these properties, IL-7 was extensively tested as an immunotherapeutic in the context of 
infections, cancer therapies and for T-cell reconstitution following BMT (42). Although these 
preclinical studies defined IL-7 as the cornerstone of T-lymphopoiesis, studies conducted in 
higher species contradicted this notion. For example, an autologous CD34+ cell transplantation 
study aimed at reconstituting peripheral T cells in non-human primates was inconsistent with 
observations made in rodent models. IL-7 administration to transplanted baboons had profound 
proliferative effects on peripheral T cells with marginal de novo thymopoiesis (43). Furthermore, 
two IL-7 phase I clinical trials conducted on cancer patients failed to provide evidence for 
thymopoiesis. In the first trial, IL-7 administration to 16 subjects with refractory malignancy 
(age ranging from 20-71 years old) led to preferential expansion of RTEs and memory T cells 
(44). The second trial, on the other hand, investigated the impact of IL-7 administration on 
gp100/MART-1-based vaccination of 12 patients aged 20-67 with metastatic melanoma/sarcoma. 
In addition to the absence of enhanced anti-tumoral effects, no significant increase in naïve T-
cell frequency was observed (45). Even though the lack of evidence for IL-7 in triggering 
thymopoiesis in higher species is yet to be clarified, IL-7 may still be clinically relevant as a 
potent adjuvant to stimulate T-cell effector functions.   
 
1.5.5 – Exploiting the IL-22/IL-22R Axis to Rebuild the Thymus 
Since its discovery in 2000, knowledge of IL-22 biology has evolved rapidly. Part of the IL-10 
cytokine family, IL-22 is produced by Th17 cells, γδ T cells, NKT cells, as well as innate 
lymphoid cells (46). Beside regulating host defenses and playing major roles in autoimmune 
pathological conditions, IL-22 has been shown to promote tissue regeneration and proliferation 
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of epithelial and stromal cells in numerous tissues including the thymus (46). Although not 
required for normal thymus organogenesis or maintenance, as no defects were detected in 
Il22−/− mice, constitutive expression of IL-22 (at a circulating range of 35-95 ng/ml of blood) at 
steady-state leads to thymic involution (48). Under thymic injury however, IL-22 is critical for 
the endogenous regeneration of thymic tissue and restoration of T-cell development as it 
promotes TEC proliferation and survival (48). A recent report even suggested that IL-22 might 
regulate Foxn1 (47), a forkhead box transcription factor critical for TEC development, 
maintenance, and regeneration (47). Although promising based on the sole available study 
conducted so far, further investigations are warranted to confirm and highlight the immuno-
regenerative potency of this new cytokine.   
 
1.5.6 - IL-21: the most recent thymopoiesis licensee 
IL-21 is the latest member of the cytokine family sharing the common γ-chain that comprises IL-
2, IL-4, IL-7, IL-9, and IL-15 (49).  The γ-chain family is central to the establishment and 
maintenance of the immune system as humans with a mutation in this receptor develop a disease 
known as X-linked severe combined immunodeficiency (XSCID), which is characterized by the 
absence of T cells and NK cells and the presence of non-functional B cells (50). The early event 
triggered by IL-21 engagement is the activation of the Janus Kinase 1 and 3 that phosphorylate 
tyrosine residues of the intracellular regions of the receptor chains (49). These phosphorylated 
regions serve as docking sites for the SH2 domains of specific signal transducers and activators 
of transcription (STAT) proteins, including STAT1, STAT3, and to a lesser extent STAT5 (49). 
Among IL-21 sensitive genes, Gzma and Gzmb encode for granzymes involved in the activity of 
cytotoxic T cells and natural killer (49). Other genes such as Bcl6, Bim and Prdm1 are major 
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regulator of B-cell survival and differentiation, while SOCS1/3 encode for negative feedback 
regulator of cytokine receptor signaling (49). Previous studies have shown that IL-21 has a 
critical role in generating Th17 and T-follicular helper (TFH) cells (51). Furthermore, IL-21 is 
able to increase interferon-γ (IFN-γ) production and cytotoxic activity of TCR-engaged CD8+ T 
cells (52). Other studies have shown that IL-21 induces the differentiation of B cells into plasma 
cells and in increasing IgG production (53).  
 
In addition to its pleotropic effects on immune cells, a novel function has been recently described 
for IL-21 in T-cell development and thymus regeneration (54-56). More specifically, in an 
attempt to study the effect of the γ-chain cytokine family on thymocytes differentiation in vitro, 
the group of Claude Perrault found that the expression of the IL-21 receptor (IL-21R) was 
strongly up-regulated on DP3 thymocytes (CD4+CD8+TCRβhiCD5med) undergoing positive 
selection (56). This up-regulation did not stimulate their differentiation (due to absent activation 
of extracellular signal-regulated kinases (ERK) by IL-21) of DP to the SP stage but was essential 
for DP3 thymocyte expansion (56). The combination of IL-21 with other differentiation-inducing 
cytokines such as IL-4, IL-7, or IL-13 generated a 3-fold increase in the number of SP CD8 T 
cells indicating that IL-21 can synergize with other cytokines for increased production of SP 
CD8 T cells (FIGURE 4). In a subsequent study by the same group, administration of IL-21 to 
mice suffering from acute thymic atrophy triggered by the synthetic glucocorticoïd 
dexamethasone (DEX) accelerated thymic recovery (54). This therapeutic effect was caused by 
the upregulation of the IL-21R on DP cells after DEX treatment which led to their proliferation. 
The study also showed that ETP, DN2, and DN3 thymocytes but not TECs express the IL-21R in 
steady-state conditions and that treatment of isolated DN cells in vitro with rIL-21 induced their  
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FIGURE 4: IN VITRO DIFFERENTIATION OF POST-SELECTED THYMOCYTES BY 
γC-CYTOKINE SIGNALING.  
IL-21 signaling induces expansion of post-selected thymocytes without CD8 lineage 
commitment, while IL-4, IL-7 and IL-13 promoted CD8 T-cell differentiation. All other tested γc 
cytokines had no effect on post-selected thymocytes (Luckey MA et al. Blood 2013) (52). 
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proliferation (54). The overall significance of these findings epitomizes rIL-21 as a potent 
pharmacological agent capable of accelerating thymic recovery following iatrogenic-induced 
thymocyte depletion or natural age-related atrophy.  
 
1.6 - Project Hypothesis 
Since thymic involution has a negative impact on the health of aged subjects, efforts were put to 
understand the causes triggering thymic involution in order to prevent or reverse it. Based on 
recent findings indicating that ETP, DN, and a subset of DP thymocytes express the IL-21R and 
expand in response to IL-21 treatment both in vitro and in vivo, we hypothesized that the 
treatment of aged mice with IL-21 will stimulate thymopoiesis leading to enhanced thymic 
function and subsequent increase in naïve T-cell output and peripheral TCR diversity. We also 
speculate that such increase in naïve T cells will render aged mice resistant to cancer due to 
improved T-cell responses following tumor-associated antigen vaccination.  
 
1.6.1 - Objective 1 
TO DISSECT THE NATURE OF T-CELL POOLS FOLLOWING IL-21 TREATMENT.  
The effect of IL-21 on de novo T-lymphopoiesis will be analyzed in three-folds. First, thymic 
subsets and generation of RTEs will be assessed in PBS- versus IL-21-treated aged mice. 
Second, flow-cytometry screening of TCRvβ-chains will be conducted to evaluate TCR 
repertoire diversity. Finally, peripheral T cells will be analyzed to obtain a global estimation of 
naïve versus memory T-cell pools. 
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1.6.2 - Objective 2 
TO EVALUATE THE SENSITIVITY AND SIGNALING ALTERATIONS FOLLOWING 
TCR STIMULATION OF ENDOGENOUS VERSUS NEWLY DEVELOPED T CELLS.  
We presume that injection of IL-21 will increase the frequency of naïve T cells with enhanced 
TCR sensitivity. To test this hypothesis, T cells derived from treated aged mice will be analyzed 
for their: i) expression profile of the phosphatases SHP-2, protein tyrosine phosphatase non-
receptor type 22 (PTPN22), and dual specificity phosphatase (DUSP5/6) known to regulate 
signaling downstream of the TCR, ii) RNA transcripts of mir-181a; the intrinsic modulator of 
TCR sensitivity, and iii) ERK1/2, lymphocyte-specific protein tyrosine kinase (Lck) and zeta-
chain-associated protein kinase 70 (ZAP-70) phosphorylation. T-cell functionalities in response 
to TCR stimulation will be assessed as well.   
 
1.6.3 - Objective 3 
TO EVALUATE THE THERAPEUTIC VALUE OF IL-21 PRE-CONDITIONING THERAPY 
ON ANTITUMORAL RESPONSES FOLLOWING VACCINATION.  
The impact of IL-21 pre-conditioning on cancer vaccination will be tested using the Trp-2 
peptide expressed on the surface of B16 melanoma cells. Briefly, aged wild-type C57Bl/6 mice 
pre-treated with PBS versus IL-21 will undergo peptide-pulsed dendritic cell-based vaccination. 
The generation of functional effector/memory T cells as well as protective responses to cancer 
challenge will be analyzed.   
 
In the present project, we propose that biological stimulation of de novo intrathymic T-
lymphopoiesis using rIL-21 will provide meaningful leads in triggering potent T-cell responses 
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in the elderly. Furthermore, this unforeseen approach will greatly tailor cancer vaccination to suit 
aged patients. 
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CHAPTRE 2 
INTERLEUKIN-21 ADMINISTRATION TO AGED MICE REJUVENATES THEIR 
PERIPHERAL T-CELL POOL BY TRIGGERING DE NOVO THYMOPOIESIS 
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2.0 - SUMMARY 
The vaccination efficacy in the elderly is significantly reduced compared to younger populations 
due to thymic involution and aged-related intrinsic changes affecting their naïve T-cell 
compartment. Interleukin (IL)-21 was recently shown to display thymostimulatory properties. 
Therefore, we hypothesised that its administration to aging hosts may improve T-cell output and 
thus, restore a competent peripheral T-cell compartment. Indeed, an increase in the production of 
recent thymic emigrants (RTEs) attributable to intrathymic expansion of early thymic 
progenitors (ETPs), double-negative (DN)-, and double-positive (DP) thymocytes as well as 
thymic epithelial cell (TEC) was observed in recombinant (r)IL-21-treated aged mice. In sharp 
contrast, no alterations in the frequency of bone marrow (BM)-derived progenitors were detected 
following rIL-21 administration. Enhanced production of naïve T cells improved the T-cell 
receptor (TCR) repertoire diversity and re-established a pool of T cells exhibiting higher levels 
of miR-181a and diminished amounts of the TCR-inhibiting phosphatases SHP-2 and DUSP5/6. 
As a result, stimulation of T cells derived from rIL-21-treated aged mice displayed enhanced 
activation of Lck, ZAP-70 and ERK, which ultimately boosted their IL-2 production, CD25 
expression, and proliferation capabilities in comparison to T cells derived from control aged 
mice. Consequently, aged rIL-21-treated mice vaccinated using a tyrosinase-related protein 2 
(Trp2)-derived peptide exhibited a substantial delay in B16 tumor growth and improved survival. 
The results of this study highlight the immunorestorative function of rIL-21 paving its use as a 
strategy for the re-establishment of effective immunity in the elderly.   
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2.1 - INTRODUCTION 
In addition for being the key site of T-lymphopoiesis in jawed vertebrates, the thymus maintains 
a competent peripheral T-cell pool with a broad spectrum of TCR specificities (Lynch et al. 
2009). It is however well established that immunity declines with aging owing to two key factors 
impeding thymic function: a defect in the survival and proliferation ability of the pre-thymic 
hematopoietic progenitor pool coupled to the precocious loss of TECs (Boehm & Swann 2013). 
These age-related changes, collectively known as thymic involution, represent major driving 
forces for homeostatic expansion of pre-existing peripheral T cells (Lynch et al. 2009). The net 
outcome culminates in TCR repertoire skewing with a noticeable increase in the number of 
effector/memory T cells (Zanni et al. 2003). Notably, a growing body of literature established 
that while the size of the peripheral T-cell compartment remains unchanged throughout aging, an 
increase in post-thymic life span of T cells takes place consequently leading to the emergence of 
T-cell intrinsic defects (Haynes & Swain 2006; Maue et al. 2009; Tsukamoto et al. 2009). For 
instance, naïve CD4+ T cells derived from aged mice display defects in TCR threshold 
calibration, do not readily form immunological synapses and have a marked reduction in the 
recruitment of TCR-associated signaling molecules when compared to younger mice (Garcia & 
Miller 1997; Tamir et al. 2000; Garcia & Miller 2001; Garcia & Miller 2002). Furthermore, 
increased expression of inhibitory receptors such as PD1, LAG3, 2B4 and CD160 were observed 
on the surface of aging CD8+ T cells (Decman et al. 2012) while both IL-2 secretion and 
proliferation potential are limited in naïve CD4+ and CD8+ T cells derived from aged mice 
(Eaton et al. 2004). Thus, stifled thymopoiesis combined to global qualitative changes affecting 
the aging peripheral T-cell pool limits the host’s ability to mount effective responses against new 
antigenic challenges and accounts for the eroded immunity commonly observed in the elderly.  
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Primarily produced by activated CD4+ T cells, IL-21 is a prominent member of the common γ-
chain family of cytokines (Spolski & Leonard 2014). In addition to its wide ranging effects on 
immune cells, IL-21 overexpression in vivo triggers potent expansion of BM-derived progenitors 
(Ozaki et al. 2006). Furthermore, we recently reported a novel mitogenic function for IL-21 on 
peptide-mediated TCR-engaged DP thymocytes using a newly developed in vitro co-culture 
system designed for T-cell differentiation (Rafei et al. 2013b). Likewise, rIL-21 administration 
to mice with glucocorticoïd-induced thymic atrophy dramatically accelerates thymic function 
recovery by stimulating the proliferation of ETPs, DN and positively selected DP thymocytes 
(Rafei et al. 2013a). Such unprecedented thymopoiesis-supporting function suggests that rIL-21 
is indeed a promising therapeutic tool endowed with the capacity of improving T-cell output in 
aged hosts owing to the expression of the IL-21 receptor (IL-21R) on both BM and thymic 
progenitors (Ozaki et al. 2006; Rafei et al. 2013a; Rafei et al. 2013b). We wished therefore to 
scrutinize whether rIL-21 administration to aged mice can rejuvenate their T-cell immunity by 
targeting de novo thymopoiesis as a mean to enhance their anti-tumoral response following 
vaccination.  
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2.2 - RESULTS 
Administration of rIL-21 enhances thymopoiesis in aged mice. 
To ensure maximal thymopoiesis-stimulating effects in vivo, we first conducted a dose response 
study in young (2 months - 2M) versus old (15 months - 15M) RAG2p-GFP mice by 
intraperitoneally (IP) administering rIL-21 (Fig. S5A). The use of the RAG2p-GFP model allows 
to easily assess de novo thymopoiesis as expression of the GFP transgene, marking newly 
developed T cells, is controlled by the Rag2 promoter activity (Monroe et al. 1999; Yu et al. 
1999; Rafei et al. 2011). Thymic analysis one week following the last injection revealed a 
progressive increase in total thymocyte absolute count in 15M but not 2M old rIL-21-treated 
mice with an optimal response rate achieved at a dose of 50ug/Kg (Fig. S5B). Similarly, only 
aged mice receiving rIL-21 exhibited an increase in the counts of all thymic subsets (DN, DP and 
single-positive) (Fig. 5A) including ETPs (Fig. 5B-C). Even though the percentage of GFP+ 
thymocytes remained unchanged in all studied groups (Fig. S5C), the increased thymic count 
observed in the rIL-21-treated aged mice was sustained over a three weeks period post-cytokine 
administration (Fig S5D). To determine whether rIL-21-enhanced thymopoiesis involves the 
expansion of BM progenitors, which could have increased their migration rate to the thymus, we 
next monitored the frequency of LSK+ cells (Lin-Sca1+c-Kit+) and its sub-populations including 
the long-term (LT; Lin-Sca1+c-Kit+CD34-CD135-) and short-term (ST; Lin-Sca1+c-
Kit+CD34+CD135-)-hematopoietic stem cells (HSCs), as well as multi-potent progenitors (MPPs; 
Lin-Sca1+c-Kit+CD34+CD135+) following rIL-21 treatment. Despite IL-21R expression on the 
surface of wild-type (WT) LT-, ST-HSCs and MPPs (Fig. S6A), the overall proportion of LSK+ 
cells (Fig. S6B) or its sub-populations (Fig. S6C) was not affected by rIL-21 administration.  
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FIGURE 5. ADMINISTRATION OF rIL-21 PROMOTES DE NOVO THYMOPOIESIS 
IN AGED BUT NOT YOUNG MICE.  
A) Counts of thymocyte sub-populations at 50ug/kg of rIL-21. B) Representative flow-cytometry 
analysis of ETPs. C) Absolute count of ETPs derived from 2M (PBS   ), 15M (PBS   ) or 15 (rIL-
21   ). D-E) Percentages of total, cTECs and mTECs in 2M (PBS    ), 15M (PBS    ) or 15M (rIL-
21  ). F) All rIL-21-treated aged mice display enhanced counts of total, cTECs and mTECs in 
comparison to PBS-treated aged mice. All data are representative of three independent 
experiments (n = 5/group with *p˂0.05, **p˂0.01, ***p˂0.001, and ****p˂0.0001).   
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Likewise, no increase in the number of LSK+ sub-populations (Fig. S6D) nor in the more 
differentiated CLP (Lin-IL-7R+Sca1+c-Kit+) population (Fig. S6E) was observed.  
 
We recently reported that TECs are devoid of IL-21R (Rafei et al. 2013a). Therefore, we 
presumed that the thymic effects observed following rIL-21 infusion strictly affect hematopoietic 
cells. Indeed, when given to aged mice, rIL-21 does not fluctuate the frequency of total TECs 
(EpCAM+CD45-), nor it did affect the ratio of cortical (c)TEC (EpCAM+CD45-UAE-1-Ly51+) 
relative to medullary (m)TECs (EpCAM+CD45-UAE-1+Ly51-/lo) populations (Fig. 5D-E). 
Conversely, absolute counts analysis showed marked improvements in the stromal compartment 
as total, cTEC and mTEC populations were significantly higher in rIL-21-treated aged mice 
compared to those derived from the PBS group (Fig. 5F). Higher production of IL-7 /thymus was 
also noticed in the rIL-21-treated aged mice compared to the control group (Fig. S5E). These 
data suggest that rIL-21 administration is beneficial to aged mice by directly targeting 
thymopoiesis in situ without triggering the expansion of BM-derived LSK+ cells.  
 
Physiological levels of RTE are restored in aged mice following rIL-21 treatment. 
To interrogate the functional relevance of rIL-21-enhanced thymopoiesis on the peripheral T-cell 
pool of aged RAG2p-GFP mice, we next assessed the percentage of circulating RTEs mirrored 
by the level of peripheral GFP+CD3ε+ T cells. In contrast to 2M old animals, where RTEs 
represent roughly 2.3% of total circulating lymphocytes, lower percentages (~0.5%) are detected 
in the peripheral blood of 15M PBS-treated aged mice (Fig. 6A). Following rIL-21 treatment, the 
percentage of GFP+CD3ε+ T cells reached a range of 1.3-1.7% over a period of three weeks post-  
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FIGURE 6. INCREASED LEVELS OF CIRCULATING RTES IN rIL-21-TREATED 
AGED MICE. 
A) Representative flow-cytometry analysis of RTEs (CD3+GFP+ T cells) in peripheral blood of 
young (2M) or aged (15M) mice 1, 2, or 3 weeks post-rIL-21 administration. Young mice (2M) 
treated with PBS were used as comparative positive controls. B-C) Analysis of overall 
percentages (B) and counts (C) of RTEs in the weeks following rIL-21 administration. The gray 
zone represents the RTE level calculated using 2M young mice (n=10) and displayed as the 
average RTE number + two S.D. Filled circles represent rIL-21-treated aged mice. D) 
Representative flow-cytometry analysis of CD45RB on the surface of all CD3+ T cells derived 
from 2M (PBS   ), 15M (PBS   ) and 15M (rIL-21  ). CD45RB isotype is displayed in black. E) 
Compiled MFIs for CD45RB expression in treated mice. All data are representative of three 
independent experiments (n = 5/group with *p˂0.05 and **p˂0.01).   
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cytokine treatment (Fig. 6A-B) with absolute numbers attaining physiological levels according to 
RTE counts calculated using blood derived from young mice (Fig. 6C).  
 
With increased encountered antigens and declined RTE levels, qualitative changes in the 
phenotype of peripheral T-cell composition occur with aging (Boursalian et al. 2004). More 
specifically, the expression of various cell surface makers including the glycoprotein CD45RB is 
down-regulated as T cells become activated and progress from a naïve to a memory phenotype 
(Tough & Sprent 1994). We therefore hypothesized that enhancing RTE generation in aged mice 
would increase the overall expression pattern of CD45RB on peripheral T-cell pool and found 
that it was indeed the case in aged mice treated with rIL-21 as depicted by histogram overlaps 
(Fig. 6D) and compiled mean fluorescent intensities (MFIs) (Fig. 6E). We therefore conclude 
that rIL-21 treatment enhances the de novo generation of RTEs, which incorporate the peripheral 
T-cell pool of aged mice. 
 
The nature of aging T-cell pool is greatly affected by rIL-21 administration. 
Following thymic egress, RTEs continue their maturation in the periphery to eventually become 
fully competent mature naïve T cells (Boursalian et al. 2004). To do so, they require access to 
secondary lymphoid organs (SLO) as a mean to encounter other cell types and cytokines required 
for their maturation (Houston et al. 2008). Although the percentage of GFP+ T cells increased 
significantly in the spleen of rIL-21-treated aged mice in the three weeks following cytokine 
treatment (Fig. 7A), the overall number of splenocytes remained steady (Fig 7B). Further in 
depth analysis revealed a progressive time-dependent increase in the absolute counts of 
GFP+CD4+ and GFP+CD8+ T cells in the spleens of rIL-21-treated aged mice (Fig. 7C)  
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FIGURE 7. AGED MICE TREATED WITH rIL-21 DISPLAY INCREASED 
PROPORTION OF NAÏVE T CELLS WITH ENHANCED TCR DIVERSITY.  
A) Percentages of GFP+ events in the spleen of 2M (PBS   ), 15M (PBS   ), and 15M (rIL-21   ) 
aged mice. B) Splenocytes counts in all experimental groups. C) Absolute counts of CD4+GFP+ 
and CD8+GFP+ T cells in 2M (PBS   ), 15M (PBS   ) and 15M (rIL-21  ) treated mice. D) A 
representative flow-cytometry analysis of naïve (CD62Lhi, CD44lo), memory (CD62LhiCD44hi) 
and effector (CD62LloCD44hi) T cells in all experimental groups. E) Compiled percentages of all 
three sub-populations in CD4+ (top panel) and CD8+ (lower panel) T cells. F) Flow-cytometry 
analysis of 15 TCRVβ-chains using peripheral CD4+ (top panel) or CD8+ (lower panel) T cells. 
All data are representative of three independent experiments (n = 5/group with *p˂0.05, 
**p˂0.01, ***p˂0.001, and ****p˂0.0001).   
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suggesting that SLO-resident aged T cells were displaced by newly migrating RTEs. We next 
examined by flow-cytometry the differentiation stages of spleen-derived CD4+ and CD8+ T cells 
and found increased abundance of T cells with a naïve phenotype (CD44loCD62Lhi) in rIL-21-
treated aged mice bolstering the notion of rIL-21-mediated enhanced T-cell output (Fig. 7D-E).  
 
Given that thymic involution compromises the TCR repertoire (Yager et al. 2008; Ahmed et al. 
2009), we continued our analysis by investigating the effect of rIL-21 administration on TCR 
diversity. To address this question, the expression profile of 15 TCRVβ-chains was analyzed on 
the surface of spleen-derived CD4+ and CD8+ T cells collected from treated mice. Significant 
improvements were observed in the proportion of Vβ2-, 6-, 8.1/8.2-, 11-, 12- and 14-expressing 
CD4+ T cells as well as Vβ2-, 5.1/5.2-, 6-, 8.1/8.2-, 8.3-, 11- and 12-expressing CD8+ T cells 
following rIL-21 administration to aging mice (Fig. 7F). These results indicate that rIL-21-
mediated de novo RTE generation is associated with major qualitative changes in the peripheral 
T-cell pool of aged mice including improved TCR diversity.  
 
Characterizing the biochemical responses of T cells. 
Thymic involution cannot solely account for impaired immune responses as additional T-cell 
intrinsic defects appear in aging naïve T cells due to prolonged post-thymic life span (Haynes & 
Swain 2006; Maue et al. 2009; Tsukamoto et al. 2009). More specifically, TCR activation is 
blunted with aging due to increased cytoplasmic concentration of phosphatases known for 
inhibiting TCR signaling (Li et al. 2012). Given such fluctuation in TCR threshold calibration, 
we next explored whether the previously observed changes in the nature of the peripheral T-cell 
pool induced by rIL-21 affect the expression levels of the TCR-targeting phosphatases SHP-2,  
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FIGURE 8. THE PERIPHERAL POOL OF T CELLS IN rIL-21-TREATED AGED MICE 
DISPLAY IMPROVED TCR SIGNALING RESPONSES. 
A) Representative western-blot analyses of phosphatases at 1, 2 or 3 weeks post-treatments of 
2M PBS (1), 15M PBS (2) and 15M rIL-21 (3) aged mice. β-actin was used as internal loading 
control. B) Compiled densitometry analysis of SHP-2, PTPN-22 and DUSP5/6 phosphatase 
expression levels. The displayed groups are: 2M (PBS   ); 15M (PBS   ); and 15M (rIL-21  ) aged 
mice. C) qPCR analysis of miR-181a in freshly isolated T cells from 2M (PBS   ); 15M (PBS   ); 
and 15M (rIL-21  ) treated mice. D) Representative intracellular flow-cytometry staining of 
pLck, pZAP-70 and pERK in 2M (PBS   ); 15M (PBS   ); and 15M (rIL-21  ) aged mice. Non-
stimulated T cells derived from young 2M mice are displayed by black histograms. All data are 
representative of three independent experiments (n = 5/group with *p˂0.05, and **p˂0.01).   
 
 
 
 
 
 
37 
 
 
C
A
D
B
2M 15M 15M 
PBS IL-21 
*
*
*
0
0.5
1.0
1.5
m
iR
-1
81
a 
R
el
at
iv
e 
Ex
pr
es
si
on
 
Fo
ld
 In
cr
ea
se
 O
ve
r 
B
as
al
 L
ev
el
s
1
2
3
4
0
** * *
1
2
3
0
1 Wk 2 Wks 3 Wks
1
2
3
0
**
* *
SHP-2
DUSP5
DUSP6
* *
PTPN-22
0.5
1.0
1.5
0
4
C
D
8
pLck
C
D
4
pZAP-70 pERK
SHP-2
1 2 3
1 Wk 2 Wks 3 Wks
1 2 3 1 2 3
β-actin
PTPN-22
1 2 3
1 Wk 2 Wks 3 Wks
1 2 3 1 2 3
β-actin
DUSP6
1 2 3
1 Wk 2 Wks 3 Wks
1 2 3 1 2 3
β-actin
DUSP5
1 2 3
1 Wk 2 Wks 3 Wks
1 2 3 1 2 3
β-actin
38 
 
PTPN-22 and DUSP5/6. Delineation of phosphatase levels by western-blotting (Fig. 8A) and 
densitometry-based quantification (Fig. 8B) revealed diminished SHP-2 and DUSP5/6 levels in  
T cells derived from rIL-21-treated aged mice at all tested time points. Only PTPN-22 remained 
unchanged in all groups throughout treatments (Fig. 8A-B). Previous studies conducted in mice 
and humans demonstrated that SHP-2 and DUSP5/6 were among several phosphatases controlled 
by miR-181a; a ~22nt microRNA molecule capable of repressing the translation of over 40 
phosphatases (Li et al. 2007). Consistently, the progressive decline in miR-181a levels observed 
in aging human naïve CD4+ T cells dovetails the decreased T-cell responsiveness following TCR 
stimulation (Li et al. 2012). To examine the possibility that rIL-21 could have reversed such 
defect through enhanced generation of RTEs expressing normal levels of miR-181a, quantitative 
(q)PCR studies were conducted using T cells sorted from spleens of treated mice. Our analysis 
revealed a 2-3 fold increase in miR-181a levels in T cells derived from rIL-21-treated aged mice 
(Fig. 8C), which is consistent with the diminished SHP-2 and DUSP5/6 levels observed earlier 
(Fig 8A-B). We next tested the responses of T cells derived from treated mice by probing early 
signaling events triggered by TCR stimulation. Although not efficient as younger lymphocytes, 
CD4+ or CD8+ T cells derived from rIL-21-treated aged mice displayed higher Lck, ZAP-70 and 
ERK phosphorylation compared to control PBS aged mice as shown by phospho-flow analysis 
(Fig. 8D). Taken collectively, these data indicate that enhanced TCR responses in the pool of T 
cells derived from rIL-21-treated aged mice is attributable to the increase in the proportion of 
naïve T cells displaying lower SHP-2 and DUSP5/6 phosphatase levels owing to improved miR-
181a expression.   
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rIL-21 administration improves the biological responses of T cells derived from aged mice. 
The dramatic reduction in naïve T-cell output coupled to the relative increase in the proportion of 
effector and central memory T cells in aged mice negatively impact T-cell responses to neo-
antigens (Yager et al. 2008). Repeated observations revealed that beside scarcity of T-cell 
precursors in the pre-immune repertoire, IL-2 production, cell surface expression of CD25 and 
T-cell proliferation are all greatly reduced in aging hosts (Haynes & Swain 2006; Maue et al. 
2009; Tsukamoto et al. 2009). Elevated secretion levels of pro-inflammatory cytokines such as 
interferon (IFN)γ caused by the accumulation of CD44hi T cells were also reported to play a role 
in accelerating age-related immunosenescence (Zhang et al. 2002; Decman et al. 2012). The 
observations made so far led us to speculate that the beneficial effect of rIL-21 on thymopoiesis 
in aged mice should improve the effector function of their rejuvenated T-cell pool. To test this 
hypothesis, spleen-derived CD3ε+ T cells were isolated three weeks following the last cytokine 
treatment (to ensure that they had completed their necessary post-thymic maturation) and 
stimulated with CD3-CD28 beads (Berkley et al. 2013). Not only were IFNγ and IL-2 secretion 
profiles by TCR-stimulated T cells derived from rIL-21-treated mice comparable to younger 
animals, but a striking decrease in IL-17 production was observed as well (Fig. 9A). In addition, 
the intensity of CD25 cell surface expression on spleen-purified TCR-stimulated CD4+ or CD8+ 
T cells and their proliferation rates were comparable between young and rIL-21-treated aged 
mice as determined by flow-cytometry (Fig 9B, D) and compiled MFIs data (Fig. 9C, E). To gain 
further insights, we quantified by qPCR the expression level of several genes known to influence 
the differentiation and/or effector function of T cells. Although no difference were observed in 
Nfat, Ap-1 and Gata3 expression in all tested groups, a decrease in T-bet and RORC (encoding 
for RORγt) transcript levels was detected in T cells derived from rIL-21-treated aged mice  
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FIGURE 9. ENHANCED BIOLOGICAL RESPONSES OF PERIPHERAL T-CELL 
POOL DERIVED FROM rIL-21-TREATED AGED MICE.   
A) IFNγ, IL-2 and IL-17 secretion quantification from T cells isolated from treated groups and 
stimulated with CD3/CD28 dynabeads for 48hrs. B) Representative flow-cytometry analysis of 
CD25 cell surface expression on CD4+ (top panel) and CD8+ (lower panel) T cells. C) Compiled 
MFIs for CD25 expression on CD4+ and CD8+ T cells. D) Representative flow-cytometry 
analysis of cell trace dilution following TCR stimulation of CD4+ (top panel) and CD8+ (lower 
panel) T cells derived from treated animals with CD3/CD28 beads. E) Compiled MFIs for cell 
trace dilution of CD4+ and CD8+ T cells following stimulation. All data are representative of 
three independent experiments (n=5/group with *p˂0.05, **p˂0.01, ***p˂0.001, and 
****p˂0.0001).   
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compared to aged PBS control mice (Fig. S7). Foxp3 expression level, on the other hand, was 
equivalent between PBS- and rIL-21-treated aged mice but significantly higher than in younger 
mice (Fig.S7). These qPCR results are consistent with the observed decrease in IFNγ (T-bet) and 
IL-17 (RORC) secretion levels and are particularly interesting as several investigations have 
associated IL-21 to autoimmune diseases (Korn et al. 2007; Peluso et al. 2007; Attridge et al. 
2012). Further analyses conducted on rIL-21-treated aged mice showed no unusual signs of 
inflammation or autoimmunity (Fig. S8). More specifically, the spleen size and weight of PBS- 
or rIL-21-treated aged mice were similar to younger mice (Fig. S8A). Total serum IgG levels 
were however lower in young mice but comparable in both PBS- and rIL-21-treated animals 
indicating an age-related factor at play independent of rIL-21 treatment (Fig. S8B). Furthermore, 
no immune infiltrates were detected in lungs, liver or kidneys of aged mice receiving rIL-21 
(Fig. S8C). In agreement with previous studies reporting accumulation of CD25+CD4+ Tregs in 
the periphery and SLO of aging mice and humans (Lages et al. 2008), we detected a significantly 
higher percentage and absolute number of spleen-derived Tregs in both PBS- and rIL-21-treated 
aged mice when compared to their younger counterparts (Fig. S8D-E). Globally, these findings 
indicate that rIL-21-mediated boosting of T-cell output in aged mice corrects the T-cell 
dysfunctionalities commonly seen with aging without inducing signs of autoimmunity.  
     
Enhanced vaccine-elicited anti-tumoral response in rIL-21-treated aged mice.  
To evaluate the effectiveness of our T-cell rejuvenation therapy, a proof-of-concept vaccination 
study was conducted using an experimental melanoma antigen (Parkhurst et al. 1998). Briefly, 
aged mice were first treated with PBS or rIL-21 according to our established protocol then left  
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FIGURE 10. T-CELL REJUVENATION OF AGED MICE ENHANCES THEIR ANTI-
TUMORAL IMMUNITY.  
A) Schematic diagram representing the timeline used for vaccination. B-C) Tumor volumes and 
percentage of tumor-free mice post-B16 tumor cell challenge in SIINFEKL-DC-vaccinated 2M 
(PBS   ); 15M (PBS   ); 15M (rIL-21   ) or Trp2-DC-vaccinated 2M (PBS   ); 15M (PBS   ); 15M 
(rIL-21  ). D) IFNγ quantification by ELISA following in vitro Trp2-stimulation of T cells 
derived from vaccinated animals. E) Representative flow-cytometry analysis of cell trace dilution 
in CD4+ and CD8+ T cells derived from vaccinated animals following in vitro Trp2 stimulation. 
F) Compiled MFIs for cell trace dilutions in CD4+ (top panel) and CD8+ (lower panel) T cells 
following in vitro Trp2 stimulation. All data are representative of three independent experiments 
(n = 5/group with *p˂0.05, **p˂0.01, and ***p˂0.001).   
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for three weeks to allow for RTE maturation (Fig. 10A). All mice were then vaccinated weekly 
(for a total of three injections) using in vitro generated BM-derived mature DCs (Fig. S9) pulsed 
with SIINFEKL (a control epitope derived from chicken ovalbumin) or SVYDFFVWL peptides 
(the experimental epitope derived from the melanoma differentiation antigen Trp2). Two weeks 
following the last DC boost, mice where challenged subcutaneously (SC) with syngeneic B16 
tumor cells and monitored thereafter for tumor growth and survival. Although all SIINFEKL-
vaccinated mice died within the same time frame (day 20-24) with no statistically significant 
difference between young, PBS- or rIL-21-treated mice, a slower tumor growth (Fig. 10B) and a 
significant delay in survival (Fig. 10C) were observed in the Trp2-vaccinated rIL-21-treated aged 
mice in comparison to the Trp2-vaccinated PBS control group (survived up to 40 versus 22 days 
respectively). We then retrieved the spleens of mice from each group and analyzed their IFNγ 
production level and proliferation following Trp2 re-stimulation in vitro. All Trp2-vaccinated 
animals responded to peptide re-stimulation with a significant increase in IFNγ response 
achieved in rIL-21-treated aged mice compared to control PBS aged mice (Fig. 10D). Similarly, 
enhanced proliferation responses were observed in the rIL-21-treated aged mice as evaluated by 
cell trace dilution overtime by flow-cytometry (Fig. 10E) and compiled MFIs data (Fig. 10F). In 
sum, these data clearly show that rIL-21 pre-conditioning of aged mice leads to marked 
improvements in the control of B16 tumor growth following Trp2 vaccination.  
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2.3 - DISCUSSION 
Thymic involution deprives aged hosts from a competent immune system capable of effectively 
responding to vaccination and invading pathogens (Boehm & Swann 2013). Although some 
aspects of age-related decline in T-cell responses reflect systemic changes, others are due to cell-
intrinsic defects (Haynes & Swain 2006; Maue et al. 2009; Tsukamoto et al. 2009). We show in 
this report that administration of rIL-21 enhances thymopoiesis in aged mice through expansion 
of both the stromal and responsive thymocytes compartments without the induction of any 
apparent pathology in peripheral organs. Consequently, a competent peripheral lymphoid pool 
containing larger proportion of naïve CD4+ and CD8+ T cells (CD62LhiCD44lo) displaying potent 
effector functions in response to TCR stimulation was restored. This increase in the availability 
and potency of naïve T cells augmented the responsiveness of aged mice to Trp2 vaccination and 
accounts for their improved survival in response to B16 tumor challenge (Fig. S10).  
 
T-lymphopoiesis remains functional at older age albeit to a limited extent (Hale et al. 2006). As 
the thymus lacks self-renewing progenitors, it heavily relies on sustained seeding with BM-
derived CLPs and/or ETPs (Min et al. 2004). Unfortunately however, BM-derived progenitor 
numbers decline markedly with age due to increased apoptosis rates as well as reduced 
proliferative capacities (Min et al. 2004). This is turn negatively impacts the delicate thymic 
stromal compartment, which is dependent on cross-talk interactions with thymic progenitors for 
its sustained survival and morphogenesis (Shores et al. 1991; Hollander et al. 1995; van Ewijk et 
al. 2000; Dudakov et al. 2012). In this regard, two major points can be concluded based on 
observations made in rIL-21-treated aged mice. First, a report by Ozaki et al. previously 
demonstrated that IL-21 overexpression in WT young mice expands LSK+ cells in vivo (Ozaki et 
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al. 2006). Such effect is certainly beneficial as it can increase the pool of BM progenitor cells 
available for thymic migration. Although we did not directly assess the level of thymus-
migrating BM progenitors, we confirmed that all LSK+ sub-populations in aging mice express 
IL-21R but fail to proliferate in response to rIL-21 administration (Fig S6). Such apparent 
discrepancy between our observations and those reported by Ozaki and colleagues may be 
explained by the lower dose or bioavailability of rIL-21 in comparison to in vivo overexpression. 
However, aged-related changes in the functional properties of LSK+ cells should also be taken 
into account. While the frequency of LT-HSCs increases drastically in the BM of aging mice, a 
decrease in the ST-HSC and the transiently reconstituting MPP populations occurs in parallel 
(confirmed in Fig. S2) (Rossi et al. 2005). Such alterations are elemental to thymopoiesis as the 
ST-HSC and MPP fractions both lie upstream of CLP and contribute to lymphoid reconstitution 
(Rossi et al. 2005). These observations are consistent with microarray analyses revealing the 
existence of systematic down-regulation of LT-HSC-specific genes mediating lymphoid 
specification and function with aging (Rossi et al. 2005). This implies that rIL-21 can 
compensate for deficiencies affecting BM-derived progenitors by stimulating the expansion of 
progenitor cells such as ETPs that have already seeded the thymic compartment. Second, the 
increase in the absolute number of cTEC and mTEC sub-populations in rIL-21-treated aged mice 
cannot be mediated by a direct action of rIL-21 due to the absence of IL-21R on TECs cell 
surface (Rafei et al. 2013a). The simplest interpretation of these results is that increased 
thymocyte numbers enhanced lympho-stromal interactions consequently promoting TECs 
expansion (Hollander et al. 1995; van Ewijk et al. 2000). Indeed, BM transplantation studies 
using RAGnull mice as recipients revealed a central role played by developing thymocytes in the 
functional organization of thymic microenvironments (van Ewijk et al. 2000). By first providing 
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signals to cTECs, DN thymocytes initiate the creation of a functional 3D organized cortical 
microenvironment. Such re-structuring facilitates the differentiation of DN thymocytes to DP 
and SP stages, which ends-up improving the survival/expansion of the mTEC compartment (van 
Ewijk et al. 2000). This is certainly a plausible explanation as the adult thymus contains non-
senescent progenitor stromal cells believed to be involved in TEC maintenance (Dumont-Lagace 
et al. 2014). Thus, an involuted stroma possibly retains the capacity to regenerate in response to 
increased progenitor numbers. Under such context, the lack of rIL-21-induced thymopoiesis in 
younger mice may not be surprising as both thymic size and function are optimal at that age.  
 
The concept that miR-181a act as a rheostat for TCR signaling is not novel (Li et al. 2007). 
Although expression of signaling molecules involved in TCR signaling is not influenced by age 
(Tamura et al. 2000), cumulative homeostatic proliferation is believed to promote progressive 
loss of miR-181a in aging naïve T cells overtime (Li et al. 2012). Only a continuous stream of 
newly developed T cells capable of replenishing the peripheral T-cell compartment can 
compensate for such intrinsic defect. In accordance with these studies, we detected lower 
expression of miR-181a in T cells of aged mice compared to their younger counterparts, which 
was further reflected on their poor TCR responsiveness (Fig. 8). However, in vivo provision of 
exogenous rIL-21 reversed the miR-181a decrease through enhanced de novo generation of 
RTEs that have incorporated the peripheral compartment. RTE maturation thereafter led to an 
increase in mature naïve T cells, which were competent enough to effectively respond to Trp2 
vaccination and trigger a substantial delay in B16 tumor growth (Figs 7, 9, and 10). There are 
however data indicating that RTEs generated in aged hosts retain some intrinsic defects 
following TCR cross-linking (Clise-Dwyer et al. 2007). If so, how can we interpret the improved 
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effector functions observed in the rejuvenated T-cell pool of rIL-21-treated mice? Clise-Dwyer et 
al. demonstrated that RTEs generated either following transplantation of younger hosts with 
aged BM or after antibody-mediated depletion of peripheral T-cell in aging hosts exhibit normal 
effector function in comparison to RTEs developed in untreated aged animals (Clise-Dwyer et al. 
2007). The authors explained this conundrum by suggesting that under lymphopenic conditions, 
levels of IL-7 are either elevated or competition for IL-7 is reduced resulting in rescued T-cell 
development. As stromal cells are the main producers of IL-7 in the thymus, an aging thymic 
microenvironment with increased TECs turnover would indeed compromise RTEs number, 
quality and function due to limited IL-7 availability. This highlight one of the distinctive 
thymopoiesis-stimulating properties of rIL-21 as it can raise the level of intrathymic IL-7 
production (Fig. S5E) most likely by indirectly mediating the expansion of the stromal 
compartment through enhanced thymocyte proliferation therefore resulting in the generation of 
defects-free RTEs.  
 
Besides physiological aging, contraction of the TCR repertoire is commonly observed in patients 
suffering from HIV infection, various cancers or following BM transplantation (van den Brink et 
al. 2004). There are currently no effective therapies capable of exerting a positive impact on 
broadening the spectrum of TCR. Studies involving IL-21R-/- mice clearly showed that IL-21 is 
dispensable for immune cell development as normal proportions of lymphocytes, monocytes, and 
granulocytes have been reported (Spolski & Leonard 2014). Our data nevertheless suggest that 
rIL-21 administration to aging hosts could have potent clinical uses related to its ability to 
promote the expansion of thymic progenitor cells, which can be further enhanced if combined 
with other thymostimulatory compounds.   
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2.4 - EXPERIMENTAL PROCEDURES 
Cell line and mice 
The syngeneic C57BL/6-derived B16F0 (B16) mouse melanoma cell line was kindly provided 
by Dr. J. Galipeau (Atlanta, GA, USA). The RAG2p-GFP transgenic mice were kindly provided 
by Dr. M. Nussenzweig (Rockefeller University, NY, USA). Female WT C57BL/6 mice were 
purchased from the Jackson Laboratory (Bar Harbor, ME). To generate IL-21R-/- C57BL/6 mice, 
commercially available sperm was purchased from the MMRRC Repository and used to fertilize 
female WT C57BL/6 mice. All mice were housed at the Institute for Research in Immunology 
and Cancer (IRIC) animal facility under specific pathogen-free conditions. All animal protocols 
were approved by the Animal Care Committee of Université de Montréal.  
 
Antibodies, cytokines and reagents 
Mouse rIL-21 and granulocyte macrophage-colony stimulating factor (rGM-CSF) were 
purchased from Peprotech (Rocky Hill, NJ, USA). All antibodies used in flow-cytometry and 
Cytofix/Cytoperm Kits used for intracellular staining were purchased from BD Pharmingen (San 
Diego, CA, USA). The anti-SHP-2, PTPN-22, DUSP5/6 and β-actin antibodies used in western-
blotting were purchased from Abcam (Cambridge, MA, USA). Quantikine ELISAs for IL-2, IL-
7, IL-17 and IFNγ were purchased from R&D System (Minneapolis, MN). The CD3-CD28 
beads, cell trace, and Trizol were purchased from Invitrogen (Burlington, ON, CA). The cell 
LyticM buffer and lipopolysaccharide (LPS) were purchased from Sigma (St-Louis, MO, USA). 
T-cell enrichment kits were purchased from StemCell Technologies (Vancouver, BC, Canada). 
The SIINFEKL and SVYDFFVWL peptides were synthesized by GenScript (Piscataway, NJ).    
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Administration of rIL-21 and T-cell analyses 
For IL-21 dosage establishment, WT young (2M) or aged (15M) female mice were IP-injected 
with various doses of rIL-21 (12, 25, 50 or 100ug/kg of weight) in 200 ul PBS on a daily interval 
(total of 5 injections) in the first week. Control mice received equal volumes of PBS. Following 
dosage identification, all subsequent in vivo experiments were performed using rIL-21 at 
50ug/kg. Peripheral T-cell absolute numbers were obtained by combining the analysis of blood 
samples collected from treated RAG2p-GFP treated mice using the Scil-Vet ABC+ 
hematological analyzer (to obtain absolute counts of lymphocytes) and flow-cytometry (to obtain 
percentages of specific sub-populations).     
 
Enrichment of primary TECs 
Primary TECs were enriched from thymic lobes of WT C57Bl/6 mice as previously described 
(Gray et al. 2006). 
 
Western-blots 
Splenocytes were first isolated from treated mice then used to sort total CD3+ T cells. Whole T-
cell extracts were then obtained through lysis using the Cell Lytic M reagent (Sigma). Extracts 
where separated by electrophoresis, transferred onto Hybond-ECL membrane, and probed using 
primary antibodies. Densitometry analysis was conducted by first imaging the chemiluminescent 
blots with the ImageQuant LAS 4000 imager (GE Healthcare Life Sciences) followed by 
analysis using the ImageQuant TL software (GE Healthcare Life Sciences). 
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Expression analysis of miR-181a 
T cells were first sorted directly in 900 μl Trizol (106 cells per tube), lysed followed by RNA was 
extraction in Trizol reagent (Invitrogen). RNA purification was further carried out using the 
RNA extraction kit (QIAgen). Reverse transcription was performed using the High Capacity 
cDNA reverse transcription kit and qPCR was performed with a 7900HT Fast Real-Time PCR 
system at IRIC’s genomic core facility. Target gene values were normalized to endogenous 
control Gapdh.  
 
Intracellular staining 
For analysis of phosphorylated (p)Lck, ZAP-70, and ERK, splenocytes were first isolated from 
treated animals prior to in vitro stimulation using CD3/CD28 dynabeads (Invitrogen) for 5 min. 
Splenocytes were then washed then surface stained for CD4 and CD8 prior to intracellular 
staining using PE-labelled primary antibodies according to manufacturer’s instructions.  
 
Histological analyses 
Chosen organs were harvested from treated mice, fixed in 10% formalin before mounting in 
paraffin. Sections were then stained with hematoxylin and eosin then scanned using the 
NanoZoomer Digital Pathology system and NPD.scan 2.3.4 software (Hamamatsu).  
 
DC vaccination and tumor challenge 
To generate DCs for vaccination, BM cells were extracted from tibia and femur bones of 8 
weeks old male mice and plated in 10 cm non-tissue culture-treated Petri dishes in 10 mL of 
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complete RPMI 1640 medium (0.048 mmol/L β-mercaptoethanol, 2 mmol/L L-glutamine, 10% 
fetal bovine serum, 2 mmol/L penicillin-streptavidin) supplemented with 10 ng/mL rGM-CSF 
(Peprotech). The media was changed at days 3 and 6 of culture. To induce DC maturation, 1 
μg/mL LPS (Sigma) was added at day 8 for 24 hours. Following confirmation of a mature 
phenotype (>80% of adherent cells were CD80+CD86+MHCI+MHCII+), DCs were pulsed with 
OVA- or Trp2-derived peptides (GeneScript) for 4 hours then harvested for intravenous 
vaccination three weeks following the last cytokine or PBS treatment. Two weeks following the 
last DC injection, vaccinated C57BL/6 mice were SC-challenged with 5×105 syngeneic B16 
tumor cells. Tumor volume was measured as [(length × width2)/2], and mice were sacrificed 
when the tumor volume reached 2000 mm3 or if it ulcerated.   
 
Proliferation and cytokine measurements  
For all assays conducted using non-vaccinated mice, total or fractionated CD4+ and CD8+ T cells 
were first isolated from individual mice by negative selection then plated at 105 cells/well in 96-
well plates. To trigger proliferation or activation, T cells were stimulated with CD3/CD28 
dynabeads in a 1:1 ratio. For in vitro re-call responses following vaccination, splenocytes were 
pulsed with 1ug/ml Trp-2 peptide. In all conditions, cells or supernatants were collected 48hrs 
post-stimulation for further analyses.   
 
Statistical analyses 
P-values were calculated using the ANOVA and Log-Rank statistical test where applicable. Log-
rank testing was performed using software available at the Walter and Eliza Hall Institute Web 
site (http://bioinf.wehi.edu.au/software/russell/logrank/).  
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2.8 - SUPPORTING INFORMATION 
FIGURE S5: Analysis of thymic GFP+ content, absolute counts and IL-7 production following 
rIL-21 administration. 
 
FIGURE S6: Administration of rIL-21 to aged mice has no beneficial effect on the BM 
compartment.   
 
FIGURE S7: Transcription factors quantification in T cells derived from treated mice. 
 
FIGURE S8: Assessment of autoimmune signs following rIL-21 administration. 
 
FIGURE S9: Generation and characterisation of BM-derived DC for vaccination.  
 
FIGURE S10: rIL-21 administration to aged mice increases thymic output leading to improved 
immune functions.  
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
SUPPLEMENTARY FIGURE S5: ANALYSIS OF THYMIC GFP+ CONTENT, 
ABSOLUTE COUNTS, AND IL-7 PRODUCTION FOLLOWING RIL-21 
ADMINISTRATION. 
A) Schematic diagram representing the strategy and group of mice used to identify the optimal 
dose of rIL-21 capable of enhancing de novo thymopoiesis. Thymi were collected and analyzed 
one week following the last rIL-21 administration. B) Total thymocyte count following 
administration of ascending doses of rIL-21 to young (2M) or aged (15M) WT female C57BL/6 
mice. C) Representative flow-cytometry analysis of thymic GFP content. D) Absolute counts of 
total thymocytes at 1, 2 or 3 weeks post-treatments. All data are representative of three 
independent experiments (n = 5/group with *p˂0.05).   
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SUPPLEMENTARY FIGURE S6: ADMINISTRATION OF RIL-21 TO AGED MICE 
HAS NO BENEFICIAL EFFECT ON THE BM COMPARTMENT.   
A) Representative flow-cytometry analysis of IL-21R expression on the surface of LT-, ST-
HSCs and MPPs derived from WT (top panel) or IL-21R-/- mice (lower panel). Filled histograms 
represent IL-21R expression. B-C) Percentages of total LSK+ cells or LT-, ST-HSCs as well as 
MPPs as depicted by flow-cytometry. D) Absolute counts of LSK+ sub-populations. e) CLP 
percentage and absolute counts in 2M (PBS   ), 15M (PBS   ), and 15M (rIL-21   ) aged mice. All 
data are representative of three independent experiments (n=5/group).   
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SUPPLEMENTARY FIGURE S7: TRANSCRIPTION FACTORS QUANTIFICATION 
IN T CELLS DERIVED FROM TREATED MICE. 
T cells derived from treated mice were isolated then lysed to extract total mRNA. qPCR analyses 
were then conducted to quantify the expression of targeted genes relative to endogenous controls. 
All data are representative of three independent experiments (n=5/group with *p˂0.05, 
***p˂0.001, and ****p˂0.0001).   
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SUPPLEMENTARY FIGURE S8: ASSESSMENT OF AUTOIMMUNE SIGNS 
FOLLOWING RIL-21 ADMINISTRATION. 
A) A representative photograph of spleens and their relative spleen to body weight derived from 
treated mice. B) Serum IgG levels quantified by ELISA. C) Hematoxylin-eosin staining of 
formalin-fixed sections of lung, liver and kidney of young, PBS- or rIL-21-treated aged mice. 
Scale bars represent 2 mm. D) Representative flow-cytometry analysis of CD4+ Tregs in all 
experimental groups. We gated on CD25+CD4+ T cells prior to FOXP3 intracellular analysis. E) 
Quantification of CD4+ Tregs according to flow-cytometry analysis and splenocyte counts. All 
data are representative of three independent experiments (n = 5/group with ***p˂0.001).   
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SUPPLEMENTARY FIGURE S9: GENERATION AND CHARACTERISATION OF 
BM-DERIVED DC FOR VACCINATION.  
A) To generate BM-derived DCs, femur and tibias of male C57BL/6 mice where flushed to 
collect total nucleated cells, which were then plated for 8 days with rGM-CSF (10ng/ml). LPS 
was added to stimulate DC maturation at day 9. B) Representative flow-cytometry analysis of 
mature DC phenotype (>80% of DCs were CD11c+CD80+CD86+H2-Kb+I-Ab+) using all non-
adherent cells collected at day 10. 
 
 
 
 
 
 
 
 
72 
 
 
 
 
 
 
 
 
 
 
 
CD3ɛ
H2-Kb
CD19
CD11c
C
D
80
C
D
86
I-A
b 83%
87%
84%
A B
BM Cells
Immature 
DCs
Phenotypic Analysis 
of Mature DCs
rGM-CSF
(8 days)
LPS
(24hrs)
73 
 
 
 
 
 
 
 
 
SUPPLEMENTARY FIGURE S10: RIL-21 ADMINISTRATION TO AGED MICE 
INCREASES THYMIC OUTPUT LEADING TO IMPROVED IMMUNE FUNCTIONS.  
In aging mice, thymopoiesis is diminished causing attrition of the TCR repertoire and 
accumulation of peripheral CD44hi T cells. In parallel, increased post-thymic life span leads to 
accumulated SHP-2 and DUSP5/6 due to decreased expression of miR-181a. As such, TCR 
stimulation of aging naïve T cells is weakened leading to lower CD25 expression along with 
poor secretion of IL-2 and thus, impaired immune functions. When given to aged mice, rIL-21 
promotes thymopoiesis leading to increased T-cell output and improved TCR diversity. As RTEs 
increase the proportion of naïve T cells expressing higher level of miR-181a, SHP-2 and 
DUSP5/6 levels diminish allowing better T-cell responses translating into potent immunity.      
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3.0 – Conclusion 
Stimulating the immune system to protect the host from infectious diseases has been a triumphal 
area of research as of the late 18th century. Since then, scientists believed in extending this 
success to generate protective cancer vaccines. Unfortunately however, this strategy was quickly 
found not to suit the elderly population due to their decline in T-cell output caused by thymic 
regression and accumulation of aged lymphocytes endowed with stimulation-related defects. 
Thus, two fundamental questions remain to be addressed: should available cancer vaccines be re-
engineered or should the elderly immunity be enhanced? The common denominator of all 
compiled data suggests that an effective cancer vaccination strategy requires the sustained 
thymic development of young and sensitive T cells capable of recognizing a panel of diversified 
targets. 
 
Although several vaccine-supportive therapies were explored, their administration was either 
ineffective, had transient effects or triggered division of aged endogenous circulating T cells 
rather than generation of new ones in the thymus. These include: i) administration of exogenous 
growth factors and cytokines, such as KGF, growth hormone, GRL, IL-7, IL-15, insulin-like 
growth factor-1, IL-12, or Flt3L; ii) adoptive transfer of T-cell precursors generated in vitro; or 
iii) the chemical or surgical ablation of sex steroids (FIGURE 11) (57). While most of these 
treatments primarily promote thymopoiesis directly, IL-22, KGF and SSA enhance thymic 
regeneration by acting on thymic stromal cells (48-36-24). Although adoptive transfer of in vitro 
generated T-cell precursors may aid in thymic regeneration, the mechanism behind its impact on 
the thymus is poorly understood but may imply improved intrathymic lympho-stromal 
interactions.  
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FIGURE 11: THE MOST PROMISING STRATEGIES DEVELOPED FOR 
REGULATION OF LYMPHOPOIESIS.  
Overview of several therapeutic approaches and their cognate targeted compartments (Dudakov 
JA et al. Trends in Immunology 2010) (54). 
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On top of previously developed strategy, we show in the present study that administration of IL-
21 to old mice stimulate thymopoiesis de novo leading to the generation of naïve T cells as 
depicted with increased accumulation of RTEs in the periphery using the RAG2-GFP model. 
Nonetheless, the observed effects were not limited on hematopoietic cells as TEC numbers were 
also improved. As a result, a highly diversified TCR repertoire was restored along with the 
appearance of a rejuvenated T-cell pool displaying improved TCR sensitivity and T-cell 
functionality (enhanced proliferation, IL-2 production and CD25 expression). Finally, we have 
shown that old mice treated with IL-21 display delayed tumor growth following Trp-2 
vaccination. Collectively, our results indicate that IL-21 acts directly on thymic progenitors 
(ETP, DN, DP thymocytes) with a significant but indirect impact on the stromal compartment 
(FIGURE 11).  
 
An NH2 terminal methionylated form of bacterially-expressed recombinant IL-21 (manufactured 
by ZymoGenetics, Inc.) was granted an orphan drug status by the FDA in 2005 for the treatment 
of patients with advanced or aggressive melanoma (59). Since then, more than a dozen clinical 
trials were conducted (clinicaltrials.gov) and revealed that IL-21 was shown to display antitumor 
activity in both renal cell carcinoma (RCC) and metastatic melanoma with partial response 
achieved in treated patients. Based on these outcomes, the therapeutic effect of IL-21 was sought 
to be enhanced if combined with other immunostimulatory agents. This hypothesis stems from 
preclinical studies showing significant antitumor effect using an in vivo model of RCC with the 
combination of IL-21 and IFN-α (60). A second study confirmed this notion by demonstrating 
that IL-21 combined with low-dose IL-2 in a melanoma mouse model substantially enhances the 
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tumor free survival compared to either agents alone (61). Although the primary objective of 
these trials was not focused on thymopoiesis, IL-21 has been reported to increase the frequency 
of highly responsive human naïve (CD62L+CD45RA+) T cells in circulation (60). As 
such, our findings will strengthen our understanding on the role played by IL-21 in thymopoiesis. 
Consequently, significant ramifications on the future use of IL-21 will emerge in the context of 
preventive/therapeutic measures aimed at enhancing immunity of the aging population 
against cancer and infectious diseases. 
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Summary
The vaccination efﬁcacy in the elderly is signiﬁcantly reduced
compared to younger populations due to thymic involution and
age-related intrinsic changes affecting their na€ıve T-cell compart-
ment. Interleukin (IL)-21 was recently shown to display thy-
mostimulatory properties. Therefore, we hypothesized that its
administration to ageing hosts may improve T-cell output and
thus restore a competent peripheral T-cell compartment. Indeed,
an increase in the production of recent thymic emigrants (RTEs)
attributable to intrathymic expansion of early thymic progenitors
(ETPs), double-negative (DN), and double-positive (DP) thymo-
cytes as well as thymic epithelial cell (TEC) was observed in
recombinant (r)IL-21-treated aged mice. In sharp contrast, no
alterations in the frequency of bone marrow (BM)-derived
progenitors were detected following rIL-21 administration.
Enhanced production of na€ıve T cells improved the T-cell receptor
(TCR) repertoire diversity and re-established a pool of T cells
exhibiting higher levels of miR-181a and diminished amounts of
the TCR-inhibiting phosphatases SHP-2 and DUSP5/6. As a result,
stimulation of T cells derived from rIL-21-treated aged mice
displayed enhanced activation of Lck, ZAP-70, and ERK, which
ultimately boosted their IL-2 production, CD25 expression, and
proliferation capabilities in comparison with T cells derived from
control aged mice. Consequently, aged rIL-21-treated mice vacci-
nated using a tyrosinase-related protein 2 (Trp2)-derived peptide
exhibited a substantial delay in B16 tumor growth and improved
survival. The results of this study highlight the immunorestora-
tive function of rIL-21 paving its use as a strategy for the
re-establishment of effective immunity in the elderly.
Key words: interleukin-21; miR-181a; T cells; thymic involu-
tion; tumor vaccine; signaling.
Introduction
In addition for being the key site of T lymphopoiesis in jawed vertebrates,
the thymus maintains a competent peripheral T-cell pool with a broad
spectrum of TCR speciﬁcities (Lynch et al., 2009). It is, however, well
established that immunity declines with ageing owing to two key factors
impeding thymic function: a defect in the survival/proliferation ability of
the prethymic hematopoietic progenitor pool coupled to the precocious
loss of TECs (Boehm & Swann, 2013). These age-related changes,
collectively known as thymic involution, represent major driving forces
for homeostatic expansion of preexisting peripheral T cells (Lynch et al.,
2009). The net outcome culminates in TCR repertoire skewing with a
noticeable increase in the number of effector/memory T cells (Zanni
et al., 2003). Notably, a growing body of literature established that
while the size of the peripheral T-cell compartment remains unchanged
throughout ageing, an increase in post-thymic lifespan of T cells takes
place consequently leading to the emergence of T-cell intrinsic defects
(Haynes & Swain, 2006; Maue et al., 2009; Tsukamoto et al., 2009). For
instance, na€ıve CD4+ T cells derived from aged mice display defects in
TCR threshold calibration, do not readily form immunological synapses,
and have a marked reduction in the recruitment of TCR-associated
signaling molecules when compared to younger mice (Garcia & Miller,
1997, 2001, 2002; Tamir et al., 2000). Furthermore, increased expres-
sion of inhibitory receptors such as PD1, LAG3, 2B4, and CD160 were
observed on the surface of ageing CD8+ T cells (Decman et al., 2012),
while both IL-2 secretion and proliferation potential are limited in na€ıve
CD4+ and CD8+ T cells derived from aged mice (Eaton et al., 2004).
Thus, stiﬂed thymopoiesis combined to global qualitative changes
affecting the ageing peripheral T-cell pool limits the host’s ability to
mount effective responses against new antigenic challenges and
accounts for the eroded immunity commonly observed in the elderly.
Primarily produced by activated CD4+ T cells, IL-21 is a prominent
member of the common c-chain family of cytokines (Spolski & Leonard,
2014). Besides its wide-ranging effects on immune cells, IL-21 overex-
pression in vivo triggers expansion of BM-derived progenitors (Ozaki
et al., 2006). Furthermore, we recently reported a novel mitogenic
function for IL-21 on peptide-mediated TCR-engaged DP thymocytes
using a newly developed in vitro coculture system designed for T-cell
differentiation (Rafei et al., 2013b). Likewise, rIL-21 administration to
mice with glucocorticoid-induced thymic atrophy dramatically acceler-
ates thymic function recovery by stimulating the proliferation of ETPs,
DN, and positively selected DP thymocytes (Rafei et al., 2013a). Such
unprecedented thymopoiesis-supporting function suggests that rIL-21 is
indeed a promising therapeutic tool endowed with the capacity of
improving T-cell output in aged hosts owing to the expression of the IL-
21 receptor (IL-21R) on both BM and thymic progenitors (Ozaki et al.,
2006; Rafei et al., 2013a,b). We wished therefore to scrutinize whether
rIL-21 administration to aged mice can rejuvenate their T-cell immunity
by targeting de novo thymopoiesis as a mean to enhance their
antitumoral response following vaccination.
Results
Administration of rIL-21 enhances thymopoiesis in aged mice
To ensure maximal thymopoiesis-stimulating effects in vivo, we ﬁrst
conducted a dose–response study in young (2 months—2M) versus old
(15 months—15M) RAG2p-GFP mice by intraperitoneally (IP) adminis-
tering rIL-21 (Fig. S1A). The use of the RAG2p-GFP model allows to easily
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assess de novo thymopoiesis as expression of the GFP transgene,
marking newly developed T cells, is controlled by the Rag2 promoter
activity (Monroe et al., 1999; Yu et al., 1999; Rafei et al., 2011). Thymic
analysis 1 week following the last injection revealed a progressive
increase in total thymocyte count in 15M but not 2M-old rIL-21-treated
mice with an optimal response rate achieved at a dose of 50 lg kg1
(Fig. S1B). Similarly, only aged mice receiving rIL-21 exhibited an increase
in the counts of all thymic subsets (DN, DP and single positive) (Fig. 1A)
including ETPs (Fig. 1B,C). Even though the percentage of GFP+
thymocytes remained unchanged in all studied groups (Fig. S1C), the
increased thymic count observed in the rIL-21-treated aged mice was
sustained over a 3-week period postcytokine administration (Fig. S1D).
To determine whether rIL-21-enhanced thymopoiesis involves the
expansion of BM progenitors, which could have increased their
migration rate to the thymus, we next monitored the frequency of
LSK cells (Lin Sca1+ c-Kit+) and its subpopulations including the
long-term (LT; Lin Sca1+ c-Kit+ CD34 CD135) and short-term (ST;
Lin Sca1+ c-Kit+ CD34+ CD135) hematopoietic stem cells (HSCs), as
well as multipotent progenitors (MPPs; Lin Sca1+ c-Kit+ CD34+
CD135+) following rIL-21 treatment. Despite IL-21R expression on the
surface of wild-type (WT) LT, ST-HSCs, and MPPs (Fig. S2A), the overall
proportion of LSK cells (Fig. S2B) or its subpopulations (Fig. S2C) was not
affected by rIL-21 administration. Likewise, no increase in the number of
LSK subpopulations (Fig. S2D) nor in the more differentiated common
lymphoid progenitor (CLP; Lin IL-7R+ Sca1+ c-Kit+) population
(Fig. S2E) was observed. Furthermore, only in vitro cultured young LSK
cells proliferated when cultured with rIL-21 (Fig. S2F) clearly suggesting a
defective response in ageing BM.
We recently reported that TECs are devoid of IL-21R (Rafei et al.,
2013a). Therefore, we presumed that the thymic effects observed
following rIL-21 infusion strictly affect hematopoietic cells. Indeed, when
given to aged mice, rIL-21 does not ﬂuctuate the frequency of total
TECs (EpCAM+ CD45), nor it did affect the ratio of cortical (c)TEC
(EpCAM+ CD45 UAE-1 Ly51+) relative to medullary (m)TEC (EpCAM+
CD45 UAE-1+ Ly51/lo) populations (Fig. 1D,E). Conversely, absolute
counts analysis showed marked improvements in the stromal
compartment as total, cTEC, and mTEC populations were signiﬁcantly
higher in rIL-21-treated aged mice compared to the PBS group (Fig. 1F).
Higher production of IL-7/thymus production was also noticed in the
rIL-21-treated aged mice (Fig. S1E). These data suggest that rIL-21
administration is beneﬁcial to aged mice by directly targeting
thymopoiesis in situ without triggering the expansion of BM-derived
LSK cells.
Physiological levels of RTE are restored in aged mice
following rIL-21 treatment
To interrogate the functional relevance of rIL-21-enhanced thymopoiesis
on the peripheral T-cell pool of aged RAG2p-GFP mice, we next assessed
the percentage of circulating RTEs mirrored by the level of peripheral
GFP+ CD3e+ T cells. In contrast to 2M-old animals, where RTEs represent
roughly 2.3% of total circulating lymphocytes, lower percentages
(~0.5%) are detected in the peripheral blood of 15M PBS-treated
aged mice (Fig. 2A). Following rIL-21 treatment, the percentage of
GFP+ CD3e+ T cells reached a range of 1.3–1.7% over a period of
3-week postcytokine treatment (Fig. 2A,B) with absolute numbers
attaining physiological levels according to RTE counts calculated using
blood derived from young mice (Fig. 2C).
With increased encountered antigens and declined RTE levels,
qualitative changes in the phenotype of peripheral T-cell composition
occur with ageing (Boursalian et al., 2004). More speciﬁcally, the
expression of various cell surface makers including the glycoprotein
CD45RB is downregulated as T cells become activated and progress from
a na€ıve to a memory phenotype (Tough & Sprent, 1994). We therefore
hypothesized that enhancing RTE generation in aged mice would
increase the overall expression pattern of CD45RB on peripheral T-cell
pool and found that it was indeed the case in aged mice treated with rIL-
21 as depicted by histogram overlaps (Fig. 2D) and compiled mean
ﬂuorescent intensities (MFIs) (Fig. 2E). We therefore conclude that rIL-21
treatment enhances the de novo generation of RTEs, which incorporate
the peripheral T-cell pool of aged mice.
The nature of ageing T-cell pool is greatly affected by rIL-21
administration
Following thymic egress, RTEs continue their maturation in the periphery
to eventually become fully competent mature na€ıve T cells (Boursalian
et al., 2004). To do so, they require access to secondary lymphoid organs
(SLO) as a mean to encounter other cell types and cytokines required for
their maturation (Houston et al., 2008). Although the percentage of
GFP+ T cells increased signiﬁcantly in the spleen of rIL-21-treated aged
mice in the 3 weeks following cytokine treatment (Fig. 3A), the overall
number of splenocytes remained steady (Fig. 3B). Further in-depth
analysis revealed a progressive time-dependent increase in the absolute
counts of GFP+ CD4+ and GFP+ CD8+ T cells in the spleens of rIL-21-
treated aged mice (Fig. 3C) suggesting that SLO-resident aged T cells
were displaced by newly migrating RTEs. We next examined by ﬂow
cytometry the differentiation stages of spleen-derived CD4+ and CD8+ T
cells and detected increased abundance of T cells with a na€ıve phenotype
(CD44loCD62Lhi) in IL-21-treated aged mice (Fig. 3D,E) bolstering the
notion of rIL-21-mediated enhanced T-cell output.
Given that thymic involution compromises the TCR repertoire (Yager
et al., 2008; Ahmed et al., 2009), we continued our analysis by
investigating the effect of rIL-21 administration on TCR diversity. To
address this question, the expression proﬁle of 15 TCRVb-chains was
analyzed on the surface of spleen-derived CD4+ and CD8+ T cells
collected from treated mice. Although no changes occurred in the
TCRVb-chains of young mice treated with PBS or rIL-21 (Fig. S3),
signiﬁcant improvements were observed in the proportion of Vb2-, 6-,
8.1/8.2-, 11-, 12-, and 14-expressing CD4+ T cells as well as Vb2-, 5.1/
5.2-, 6-, 8.1/8.2-, 8.3-, 11-, and 12-expressing CD8+ T cells following rIL-
21 administration to ageing mice (Fig. 3F). These results indicate that rIL-
21-mediated de novo RTE generation is associated with major qualitative
changes in the peripheral T-cell pool of aged mice including improved
TCR diversity.
Characterizing the biochemical responses of T cells
Thymic involution cannot solely account for impaired immune responses
as additional T-cell intrinsic defects appear in ageing na€ıve T cells due to
prolonged post-thymic lifespan (Haynes & Swain, 2006; Maue et al.,
2009; Tsukamoto et al., 2009). More speciﬁcally, TCR activation is
blunted with ageing due to increased cytoplasmic concentration of
phosphatases known for inhibiting TCR signaling (Li et al., 2012). Given
such ﬂuctuation in TCR threshold calibration, we next explored whether
the previously observed changes in the nature of the peripheral T-cell
pool induced by rIL-21 affect the expression levels of the TCR-targeting
phosphatases SHP-2, PTPN-22, and DUSP5/6. Delineation of phos-
phatase levels by Western blotting (Fig. 4A) and densitometry-based
quantiﬁcation (Fig. 4B) revealed diminished SHP-2 and DUSP5/6 levels in
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Fig. 1 Administration of rIL-21 promotes de novo thymopoiesis in aged but not young mice. (A) Counts of thymocyte subpopulations. Groups are displayed as
PBS (■) and IL-21 (□). (B) Representative ﬂow cytometry analysis of ETPs. (C) Absolute count of ETPs. (D, E) Percentages of total, cTECs, and mTECs. (F) Absolute
counts of total, cTECs, and mTECs in comparison with PBS-treated aged mice. For panels C, E, and F, groups are displayed as: 2M (PBS ), 15M (PBS □), or 15M (rIL-21 ■).
All data are representative of three independent experiments (n = 5/group with *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).
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T cells derived from rIL-21-treated aged mice at all tested time points.
Only PTPN-22 remained unchanged in all groups throughout treatments
(Fig. 4A,B). Previous studies conducted in mice demonstrated that SHP-2
and DUSP5/6 were among several phosphatases controlled by miR-181a,
a ~22nt microRNA molecule capable of repressing the translation of over
40 phosphatases (Li et al., 2007). Consistently, the progressive decline in
miR-181a levels observed in ageing human na€ıve CD4+ T cells dovetails
the decreased T-cell responsiveness following TCR stimulation (Li et al.,
2012). To examine the possibility that rIL-21 could have reversed such
defect through enhanced generation of RTEs expressing normal levels of
miR-181a, quantitative (q)PCR studies were conducted using T cells
sorted from spleens of treated mice. Our analysis revealed a two- to
threefold increase in miR-181a levels in T cells derived from rIL-21-
treated aged mice (Fig. 4C), which is consistent with the diminished
SHP-2 and DUSP5/6 levels observed earlier (Fig. 4A,B). We next tested
the responses of T cells derived from treated mice by probing early
signaling events triggered by TCR stimulation. Although not efﬁcient as
younger lymphocytes, CD4+ or CD8+ T cells derived from rIL-21-treated
aged mice displayed higher Lck, ZAP-70, and ERK phosphorylation
compared to control PBS aged mice as shown by phospho-ﬂow analysis
(Fig. 4D). Taken collectively, these data indicate that enhanced TCR
responses in the pool of T cells derived from rIL-21-treated aged mice are
attributable to the increase in the proportion of na€ıve T cells displaying
lower SHP-2 and DUSP5/6 phosphatase levels owing to improved miR-
181a expression.
rIL-21 administration improves the biological responses of T
cells derived from aged mice
The dramatic reduction in na€ıve T-cell output coupled to the relative
increase in the proportion of effector and central memory T cells in aged
mice negatively impact T-cell responses to neo-antigens (Yager et al.,
2008). Repeated observations revealed that beside scarcity of T-cell
precursors in the pre-immune repertoire, IL-2 production, cell surface
expression of CD25, and T-cell proliferation are all greatly reduced in
ageing hosts (Haynes & Swain, 2006; Maue et al., 2009; Tsukamoto
et al., 2009). Elevated secretion levels of pro-inﬂammatory cytokines
such as interferon (IFN)c caused by the accumulation of CD44hi T cells
were also reported to play a role in accelerating age-related immunose-
nescence (Zhang et al., 2002; Decman et al., 2012). The observations
made so far led us to speculate that the beneﬁcial effect of rIL-21 on
thymopoiesis in aged mice should improve the effector function of their
rejuvenated T-cell pool. To test this hypothesis, spleen-derived CD3e+ T
cells were isolated 3 weeks following the last cytokine treatment (to
ensure that they had completed their necessary post-thymic maturation)
and stimulated using CD3-CD28 beads (Berkley et al., 2013). Not only
were IFNc and IL-2 secretion proﬁles by TCR-stimulated T cells derived
from rIL-21-treated mice comparable to younger animals, but a striking
decrease in IL-17 production was observed as well (Fig. 5A). In addition,
the intensity of CD25 cell surface expression on spleen-puriﬁed TCR-
stimulated CD4+ or CD8+ T cells and their proliferation rates were
comparable between young and rIL-21-treated aged mice as determined
by ﬂow cytometry (Fig. 5B,D) and compiled MFIs data (Fig. 5C,E). To
gain further insights, we quantiﬁed by qPCR the expression level of
several genes known to inﬂuence the differentiation and/or effector
function of T cells. Although no difference was observed in Nfat, Ap-1,
and Gata3 expression in all tested groups, a decrease in T-bet and RORC
(encoding for RORct) transcript levels was detected in T cells derived
from rIL-21-treated aged mice compared to aged PBS control mice
(Fig. S4). Foxp3 expression level, on the other hand, was equivalent
between PBS- and rIL-21-treated aged mice but signiﬁcantly higher than
younger mice (Fig. S4). These qPCR results are consistent with the
observed decrease in IFNc (T-bet) and IL-17 (RORC) secretion levels and
are particularly interesting as several investigations have associated IL-21
to autoimmune diseases (Korn et al., 2007; Peluso et al., 2007; Attridge
et al., 2012). Further analyses conducted on rIL-21-treated aged mice
showed no unusual signs of inﬂammation or autoimmunity (Fig. S5).
More speciﬁcally, we found (i) that the spleen size and weight of PBS- or
rIL-21-treated aged mice were similar to younger mice (Fig. S5A), (ii) that
the total serum IgG levels were lower in young mice but comparable in
both PBS- and rIL-21-treated animals indicating an age-related factor at
play independent of rIL-21 treatment (Fig. S5B), and (iii) no immune
inﬁltrates in lungs, liver, or kidneys of aged mice receiving rIL-21
(Fig. S5C). In agreement with previous studies reporting accumulation of
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CD25+ CD4+ Tregs in the periphery and SLO of ageing mice and humans
(Lages et al., 2008), we detected a signiﬁcantly higher percentage and
absolute number of spleen-derived Tregs in both PBS- and rIL-21-treated
aged mice when compared to their younger counterparts (Fig. S5D,E).
Globally, these ﬁndings indicate that rIL-21-mediated boosting of T-cell
output in aged mice corrects the T-cell dysfunctionalities commonly seen
with ageing without inducing signs of autoimmunity.
Enhanced vaccine-elicited antitumoral response in rIL-21-
treated aged mice
To evaluate the effectiveness of our T-cell rejuvenation therapy, a
proof-of-concept vaccination study was conducted using an experi-
mental melanoma antigen (Parkhurst et al., 1998). Brieﬂy, aged mice
were ﬁrst treated with PBS or rIL-21 according to our established
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protocol, then left for 3 weeks to allow for RTE maturation (Fig. 6A).
All mice were then vaccinated weekly (for a total of three injections)
using in vitro generated BM-derived mature DCs (Fig. S6) pulsed with
SIINFEKL (a control epitope derived from chicken ovalbumin) or
SVYDFFVWL peptides (the experimental epitope derived from the
melanoma differentiation antigen Trp2). Two weeks following the last
DC boost, mice were challenged subcutaneously (SC) with syngeneic
B16 tumor cells and monitored thereafter for tumor growth and
survival. Although all SIINFEKL-vaccinated mice died within the same
time frame (day 20–24) with no statistically signiﬁcant difference
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between young, PBS-, or rIL-21-treated mice, a slower tumor growth
(Fig. 6B) and a signiﬁcant delay in survival (Fig. 6C) were observed in
the Trp2-vaccinated rIL-21-treated aged mice in comparison with the
Trp2-vaccinated PBS control group (survived up to 40 versus 22 days,
respectively). We then retrieved the spleens of mice from each group
and analyzed their IFNc production level and proliferation following
Trp2 restimulation in vitro. All Trp2-vaccinated animals responded to
peptide restimulation with a signiﬁcant increase in IFNc response
achieved in rIL-21-treated aged mice compared to control PBS aged
mice (Fig. 6D). Similarly, enhanced proliferation responses were
B
A
C
E
FD
Fig. 6 T-cell rejuvenation of aged mice enhances their antitumoral immunity. (A) Timeline used for vaccination. (B, C) Tumor volumes and percentage of tumor-free mice
post-B16 tumor cell challenge in OVAp-DC-vaccinated 2M (PBS ■), 15M (PBS▼), and 15M (rIL-21●); or Trp2p-DC-vaccinated 2M (PBS ), 15M (PBS ) and 15M (rIL-21 ).
(D) IFNc quantiﬁcation following in vitro Trp2p stimulation of T cells derived from vaccinated animals. (E) Representative ﬂow cytometry analysis of cell trace dilution in CD4+
and CD8+ T cells derived from vaccinated animals following in vitro Trp2 stimulation. (F) Compiled MFIs for cell trace dilutions in CD4+ (top panel) and CD8+ (lower panel) T
cells following in vitro Trp2 stimulation. OVAp (SIINFEKL) and Trp2p (SVYDFFVWL). All data are representative of three independent experiments (n = 5/group with
*P < 0.05, **P < 0.01, and ***P < 0.001).
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observed in the rIL-21-treated aged mice as evaluated by cell trace
dilution overtime by ﬂow cytometry (Fig. 6E) and compiled MFIs data
(Fig. 6F). In sum, these data clearly show that rIL-21 preconditioning of
aged mice leads to marked improvements in the control of B16 tumor
growth following Trp2 vaccination.
Discussion
Thymic involution deprives aged hosts from a competent immune
system capable of effectively responding to vaccination and invading
pathogens (Boehm & Swann, 2013). Although some aspects of age-
related decline in T-cell responses reﬂect systemic changes, others are
due to cell intrinsic defects (Haynes & Swain, 2006; Maue et al.,
2009; Tsukamoto et al., 2009). We show in this report that
administration of rIL-21 enhances thymopoiesis in aged mice through
expansion of both the stromal and responsive thymocytes compart-
ments without the induction of any apparent pathology in peripheral
organs. Consequently, a competent peripheral lymphoid pool con-
taining larger proportion of na€ıve CD4+ and CD8+ T cells (CD62LhiC-
D44lo) displaying potent effector functions in response to TCR
stimulation was restored. This increase in the availability and potency
of na€ıve T cells augmented the responsiveness of aged mice to Trp2
vaccination and accounts for their improved survival in response to
B16 tumor challenge (Fig. S7).
T lymphopoiesis remains functional at older age albeit to a limited
extent (Hale et al., 2006). As the thymus lacks self-renewing progen-
itors, it heavily relies on sustained seeding with BM-derived CLPs and/or
ETPs (Min et al., 2004). Unfortunately, however, BM-derived progenitor
numbers decline markedly with age due to increased apoptosis rates as
well as reduced proliferative capacities (Min et al., 2004). This in turn
negatively impacts the delicate thymic stromal compartment, which is
dependent on cross talk interactions with thymic progenitors for its
sustained survival and morphogenesis (Shores et al., 1991; Hollander
et al., 1995; van Ewijk et al., 2000; Dudakov et al., 2012). In this
regard, two major points can be concluded based on observations
made in rIL-21-treated aged mice. First, a report by Ozaki et al.
previously demonstrated that IL-21 overexpression in WT young mice
expands LSK cells in vivo (Ozaki et al., 2006). Such effect is certainly
beneﬁcial as it can increase the pool of BM progenitor cells available
for thymic migration. Although we did not directly assess the level of
thymus-migrating BM progenitors, we conﬁrmed that all LSK subpop-
ulations in ageing mice express IL-21R but fail to proliferate in response
to rIL-21 administration (Fig. S2). Such apparent discrepancy between
our observations and those reported by Ozaki and colleagues may be
explained by the lower dose or bioavailability of rIL-21 in comparison
with in vivo overexpression. However, age-related changes in the
functional properties of LSK cells should also be taken into account.
While the frequency of LT-HSCs increases drastically in the BM of
ageing mice, a decrease in the ST-HSC and the transiently reconsti-
tuting MPP populations occurs in parallel (conﬁrmed in Fig. S2) (Rossi
et al., 2005). Such alterations are elemental to thymopoiesis as the ST-
HSC and MPP fractions both lie upstream of CLP and contribute to
lymphoid reconstitution (Rossi et al., 2005). These observations are
consistent with microarray analyses revealing the existence of system-
atic downregulation of LT-HSC-speciﬁc genes mediating lymphoid
speciﬁcation and function with ageing (Rossi et al., 2005). This implies
that rIL-21 can compensate for deﬁciencies affecting BM-derived
progenitors by stimulating the expansion of progenitor cells such as
ETPs that have already seeded the thymic compartment. Second, the
increase in the absolute number of cTEC and mTEC subpopulations in
rIL-21-treated aged mice cannot be mediated by a direct action of rIL-
21 due to the absence of IL-21R on TEC surface (Rafei et al., 2013a).
The simplest interpretation of these results is that increased thymocyte
numbers enhanced lympho-stromal interactions consequently promot-
ing TECs expansion (Hollander et al., 1995; van Ewijk et al., 2000).
Indeed, BM transplantation studies using RAGnull mice as recipients
revealed a central role played by developing thymocytes in the
functional organization of thymic microenvironments (van Ewijk et al.,
2000). By ﬁrst providing signals to cTECs, DN thymocytes initiate the
creation of a functional 3D organized cortical microenvironment. Such
restructuring facilitates the differentiation of DN thymocytes to DP and
SP stages, which ends up improving the survival/expansion of the mTEC
compartment (van Ewijk et al., 2000). This is certainly a plausible
explanation as the adult thymus contains nonsenescent progenitor
stromal cells believed to be involved in TEC maintenance (Dumont-
Lagace et al., 2014). Thus, an involuted stroma possibly retains the
capacity to regenerate in response to increased progenitor numbers.
Under such context, the lack of rIL-21-induced thymopoiesis in younger
mice may not be surprising as both thymic size and function are
optimal at that age.
The concept that miR-181a acts as a rheostat for TCR signaling is
not novel (Li et al., 2007). Although expression of signaling molecules
involved in TCR signaling is not inﬂuenced by age (Tamura et al.,
2000), cumulative homeostatic proliferation is believed to promote
progressive loss of miR-181a in ageing na€ıve T cells overtime (Li et al.,
2012). Only a continuous stream of newly developed T cells capable of
replenishing the peripheral T-cell compartment can compensate for
such intrinsic defect. In accordance with these studies, we detected
lower expression of miR-181a in T cells of aged mice compared to their
younger counterparts, which was further reﬂected on their poor TCR
responsiveness (Fig. 4). However, in vivo provision of exogenous rIL-21
reversed the miR-181a decrease through enhanced de novo generation
of RTEs that have incorporated the peripheral compartment. RTE
maturation thereafter led to an increase in mature na€ıve T cells, which
were competent enough to effectively respond to Trp2 vaccination and
trigger a substantial delay in B16 tumor growth (Figs 3, 5, and 6). This,
however, does not preclude the possibility that rIL-21 administration to
aged mice affects other preexisting immune cells in periphery.
Additional studies involving thymectomized mice or adoptive transfer
into athymic nude are required to conﬁrm this hypothesis. In addition,
there are data indicating that RTEs generated in aged hosts retain some
intrinsic defects following TCR cross-linking (Clise-Dwyer et al., 2007).
If so, how can we interpret the improved effector functions observed in
the rejuvenated T-cell pool of rIL-21-treated mice? Clise-Dwyer et al.
demonstrated that RTEs generated either following transplantation of
younger hosts with aged BM or after antibody-mediated depletion of
peripheral T-cell in ageing hosts exhibit normal effector function in
comparison with RTEs developed in untreated aged animals (Clise-
Dwyer et al., 2007). The authors explained this conundrum by
suggesting that under lymphopenic conditions, levels of IL-7 are either
elevated or competition for IL-7 is reduced resulting in rescued T-cell
development. As stromal cells are the main producers of IL-7 in the
thymus, an ageing thymic microenvironment with increased TECs
turnover would indeed compromise RTEs number, quality, and function
due to limited IL-7 availability. This highlights one of the distinctive
thymopoiesis-stimulating properties of rIL-21 as it can raise the level of
intrathymic IL-7 production (Fig. 1SE) most likely by indirectly mediating
the expansion of the stromal compartment through enhanced thymo-
cyte proliferation therefore resulting in the generation of defects-free
RTEs.
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Besides physiological ageing, contraction of the TCR repertoire is
commonly observed in patients suffering from infections, cancers, or
following BM transplantation (van den Brink et al., 2004). There are
currently no effective therapies capable of exerting a positive impact on
broadening the spectrum of TCR. Studies involving IL-21R/mice clearly
showed that IL-21 is dispensable for immune cell development as normal
proportions of lymphocytes, monocytes, and granulocytes have been
reported (Spolski & Leonard, 2014). Our data nevertheless suggest that
rIL-21 administration to ageing hosts could have potent clinical uses
related to its ability to promote the expansion of thymic progenitor cells,
which can be further enhanced if combined with other thymostimulatory
compounds.
Experimental procedures
Cell line and mice
The B16F0 mouse melanoma cell line was kindly provided by Dr. J.
Galipeau (Atlanta, GA, USA). The RAG2p-GFP transgenic mice were
kindly provided by Dr. M. Nussenzweig (Rockefeller University, New
York, NY, USA). Female WT C57BL/6 mice were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA). To generate IL-21R/
C57BL/6 mice, commercially available sperm was purchased from the
MMRRC repository and used to fertilize female WT C57BL/6 mice. All
mice were housed at the Institute for Research in Immunology and
Cancer (IRIC) animal facility under speciﬁc pathogen-free conditions. All
animal protocols were approved by the Animal Care Committee of
Universite de Montreal.
Antibodies, cytokines and reagents
Mouse rIL-21 and granulocyte–macrophage colony-stimulating factor
(rGM-CSF) were purchased from Peprotech (Rocky Hill, NJ, USA). All ﬂow
cytometry antibodies and Cytoﬁx/Cytoperm Kits were purchased from
BD Pharmingen (San Diego, CA, USA). The anti-SHP-2, PTPN-22, DUSP5/
6, and b-actin antibodies used in Western blotting were purchased from
Abcam (Cambridge, MA, USA). Quantikines were purchased from R&D
System (Minneapolis, MN, USA). The CD3-CD28 beads, cell trace, and
Trizol were purchased from Invitrogen (Burlington, ON, Canada). The cell
Lytic M buffer and lipopolysaccharide (LPS) were purchased from Sigma
(St-Louis, MO, USA). T-cell enrichment kits were purchased from
StemCell Technologies (Vancouver, BC, Canada). Peptides were synthe-
sized by GenScript (Piscataway, NJ, USA).
Administration of rIL-21 and T-cell analyses
For IL-21 dosage establishment, WT young (2M), or aged (15M) female
mice were IP-injected with rIL-21 in 200 lL PBS on a daily interval (total
of ﬁve injections) in the ﬁrst week. Control mice received equal volumes
of PBS. All subsequent in vivo experiments were performed using rIL-21
at 50 lg kg1. Peripheral T-cell absolute numbers were obtained by
combining the analysis of blood samples collected from treated RAG2p-
GFP mice using the Scil-Vet ABC+ hematological analyzer (to obtain
absolute counts of lymphocytes) and ﬂow cytometry (to obtain
percentages of speciﬁc subpopulations).
Enrichment of primary TECs
Primary TECs were enriched from thymic lobes of WT C57Bl/6 mice as
previously described (Gray et al., 2006).
Western blots
Splenocytes were ﬁrst isolated to sort total CD3+ T cells. Whole T-cell
extracts were obtained through using the Cell Lytic M reagent (Sigma).
Extracts were separated by electrophoresis, transferred onto Hybond-
ECL membrane, and probed using primary antibodies. Densitometry
analysis was conducted by ﬁrst imaging the chemiluminescent blots with
the ImageQuant LAS 4000 imager (GE Healthcare Life Sciences,
Mississauga, ON, Canada) followed by analysis using the ImageQuant
TL software (GE Healthcare Life Sciences).
Expression analysis of miR-181a
T cells were ﬁrst sorted directly in 900 lL Trizol (106 cells per tube) and
lysed followed by RNA extraction in Trizol reagent (Invitrogen). RNA
puriﬁcation was further carried out using the RNA extraction kit (QIAgen,
Toronto, On, Canada). Reverse transcription was performed using the
High Capacity cDNA reverse transcription kit and qPCR was performed
with a 7900HT Fast Real-Time PCR system at IRIC’s genomic core facility.
Target gene values were normalized to endogenous control Gapdh.
Intracellular staining
For analysis of phosphorylated (p)Lck, ZAP-70, and ERK, isolated
splenocytes were ﬁrst stimulated in vitro using CD3-CD28 Dynabeads
(Invitrogen) for 5 min, then washed and surface stained for CD4 and
CD8 prior to intracellular staining according to manufacturer’s instruc-
tions.
Histological analyses
Chosen organs were harvested from treated mice, ﬁxed in 10% formalin
before mounting in parafﬁn. Sections were then stained with hema-
toxylin and eosin, then scanned using the NanoZoomer Digital Pathology
system and NPD.scan 2.3.4 software (Hamamatsu, Hamamatsu city,
Japan).
DC vaccination and tumor challenge
To generate DCs for vaccination, BM cells were extracted from tibia/
femur bones of 8-week-old male mice and plated in 10-cm nontissue
culture-treated Petri dishes containing 10 mL of complete RPMI 1640
medium (0.048 mmol L1 b-mercaptoethanol, 2 mmol L1 L-glutamine,
10% fetal bovine serum, 2 mmol L1 penicillin–streptavidin) supple-
mented with 10 ng mL1 rGM-CSF (Peprotech). The media were
changed at days 3 and 6 of culture. To induce DC maturation,
1 lg mL1 LPS (Sigma) was added at day 8 for 24 h. Following
conﬁrmation of a mature phenotype (>80% of adherent cells were
CD80+ CD86+ MHCI+ MHCII+), DCs were pulsed with OVA- or Trp2-
derived peptides (GenScript) for 4 h, then harvested for intravenous
vaccination. Two weeks following the last boost, mice were SC-
challenged with 5 9 105 B16 tumor cells. Tumor volume was measured
as [(length 9 width2)/2], and mice were sacriﬁced when the tumor
volume reached 2000 mm3.
Proliferation and cytokine measurements
For all assays conducted using nonvaccinated mice, total or fractionated
T cells were ﬁrst isolated by negative selection, then plated at
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105 cells well1 in 96-well plates. To trigger proliferation/activation, T
cells were stimulated with CD3-CD28 Dynabeads in a 1:1 ratio. For
in vitro recall responses following vaccination, splenocytes were pulsed
with 1 lg mL1 Trp2 peptide. Cells or supernatants were collected 48 h
poststimulation for further analyses.
Statistical analyses
P-values were calculated using the ANOVA and log-rank statistical test
where applicable. Log-rank testing was performed using software
available at the Walter and Eliza Hall Institute Web site (http://
bioinf.wehi.edu.au/software/russell/logrank/).
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Supplementary Figure S1: Analysis of thymic GFP+ content, absolute counts and IL-7 
production following rIL-21 administration. 
A) Schematic diagram representing the strategy and group of mice used to identify the optimal 
dose of rIL-21 capable of enhancing de novo thymopoiesis. Thymi were collected and analyzed 
one week following the last rIL-21 administration. B) Total thymocyte count following 
administration of ascending doses of rIL-21 to young (2M) or aged (15M) WT female C57BL/6 
mice. C) Representative flow-cytometry analysis of thymic GFP content. D) Absolute counts of 
total thymocytes in 2M (PBS   ) or 15M (PBS   ) 1 week post-PBS treatment versus 15M (rIL-21     
   ) at 1, 2, and 3 weeks post-rIL-21 treatment. E) ELISA-based quantification of IL-7 secretion 
by thymus one week post-treatment. All data are representative of three independent experiments 
(n = 5/group with *p˂0.05).   
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Supplementary Figure S2: Administration of rIL-21 to aged mice has no beneficial effect 
on the BM compartment.   
A) Representative flow-cytometry analysis of IL-21R expression on the surface of LT-, ST-
HSCs and MPPs derived from WT (top panels) or IL-21R-/- mice (lower panels). Filled 
histograms represent IL-21R expression. B-C) Percentages of total LSK cells or LT-, ST-HSCs 
as well as MPPs as depicted by flow-cytometry. D) Absolute counts of LSK sub-populations in 
2M (PBS   ), 15M (PBS   ), and 15M (rIL-21  ) aged mice. E) CLP percentage and absolute 
counts in 2M (PBS   ), 15M (PBS   ), and 15M (rIL-21   ) aged mice. F) Absolute counts of LSK 
derived from young or aged mice following in vitro PBS or rIL-21 treatment. All data are 
representative of three independent experiments (n=5/group with *p˂0.05; **p˂0.01, and 
***p˂0.001).   
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Supplementary figure S3. Assessment of TCR repertoire diversity following rIL-21 
administration to young mice. 
Flow-cytometry analysis of 15 TCRVβ-chains using spleen-derived CD4+ (top panel) or CD8+ 
(lower panel) T cells from young 2M old mice treated with PBS (black bars) or rIL-21 (white 
bard). No significant differences were depicted between both groups. All data are representative 
of three independent experiments (n = 5/group).   
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Supplementary Figure S4: Transcription factors quantification in T cells derived from 
treated mice. 
T cells derived from treated mice were isolated then lysed to extract total mRNA. qPCR analyses 
were then conducted to quantify the expression of targeted genes relative to endogenous controls. 
Groups are displayed as: 2M (PBS   ); 15M (PBS   ); and 15M (rIL-21  ) aged mice. All data are 
representative of three independent experiments (n=5/group with *p˂0.05, ***p˂0.001, and 
****p˂0.0001).   
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Supplementary Figure S5: Assessment of autoimmune signs following rIL-21 
administration. 
A) A representative photograph of spleens and their relative spleen to body weight derived from 
treated mice. B) Serum IgG levels quantified by ELISA. C) Hematoxylin-eosin staining of 
formalin-fixed sections of lung, liver and kidney of young, PBS- or rIL-21-treated aged mice. 
Scale bars represent 2 mm. D) Representative flow-cytometry analysis of CD4+CD25+ Tregs in all 
experimental groups. We pre-gated on CD4+ T cells prior to CD25+ (cell surface) and FOXP3 
(intracellular) analysis. E) Quantification of CD4+CD25+ Tregs according to flow-cytometry 
analysis and splenocyte counts. All data are representative of three independent experiments (n = 
5/group with ***p˂0.001).   
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Supplementary Figure S6: Generation and characterisation of BM-derived DC for 
vaccination.  
A) To generate BM-derived DCs, femur and tibias of male C57BL/6 mice where flushed to 
collect total nucleated cells, which were then plated for 8 days with rGM-CSF (10ng/ml). LPS 
was added to stimulate DC maturation at day 9. B) Representative flow-cytometry analysis of 
mature DC phenotype (>80% of DCs were CD11c+CD80+CD86+H2-Kb+I-Ab+) using all non-
adherent cells collected at day 10. 
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Supplementary Figure S7: rIL-21 administration to aged mice increases thymic output 
leading to improved immune functions.  
In aging mice, thymopoiesis is diminished causing attrition of the TCR repertoire and 
accumulation of peripheral CD44hi T cells. In parallel, increased post-thymic life span leads to 
accumulated SHP-2 and DUSP5/6 due to decreased expression of miR-181a. As such, TCR 
stimulation of aging naïve T cells is weakened leading to lower CD25 expression along with 
poor secretion of IL-2 and thus, impaired immune functions. When given to aged mice, rIL-21 
promotes thymopoiesis leading to increased T-cell output and improved TCR diversity. As RTEs 
increase the proportion of naïve T cells expressing higher level of miR-181a, SHP-2 and 
DUSP5/6 levels diminish allowing better T-cell responses translating into potent immunity.      
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